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A B S T R A C T
Background
Low cost, non-invasive alterations in lifestyle are frequently recommended by healthcare professionals or those presenting with incon-
tinence. However, such recommendations are rarely based on good evidence.
Objectives
The objective of the review was to determine the effectiveness of specific lifestyle interventions (i.e. weight loss; dietary changes; fluid
intake; reduction in caffeinated, carbonated and alcoholic drinks; avoidance of constipation; stopping smoking; and physical activity)
in the management of adult urinary incontinence.
Search methods
We searched theCochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE and MEDLINE in process, and handsearching of journals and conference proceedings
(searched 3 July 2013), and the reference lists of relevant articles. We incorporated the results of these searches fully in the review. We
undertook an updated search of the Specialised Register, which now includes searches of ClinicalTrials.gov and WHO ICTRP, on 27
October 2014; potentially eligible studies from this search are currently awaiting classification.
Selection criteria
Randomised and quasi-randomised studies of community-based lifestyle interventions compared with no treatment, other conservative
therapies, or pharmacological interventions for the treatment of urinary incontinence in adults.
Data collection and analysis
Two authors independently assessed study quality and extracted data. We collected information on adverse effects from the trials. Data
were combined in a meta-analysis when appropriate. We assessed the quality of the evidence using the GRADE approach.
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Main results
We included 11 trials in the review, involving a total of 5974 participants.
Four trials involving 4701 women compared weight loss programmes with a control intervention. Low quality evidence from one trial
suggested that more women following weight loss programmes reported improvement in symptoms of incontinence at six months
(163/214 (76%) versus 49/90 (54%), risk ratio (RR) 1.40, 95% confidence interval (CI) 1.14 to 1.71), and this effect was sustained
at 18 months (N = 291, 75% versus 62%, RR not estimable, reported P value 0.02). No data were available for self-reported cure and
quality of life. One of the weight loss trials involving 1296 women reported very low quality evidence for a reduction in weekly urinary
incontinence a mean of 2.8 years after following a lifestyle weight loss intervention that had been compared with a pharmacological
weight loss intervention.
Three trials involving 181 women and 11 men compared change in fluid intake with no change. Limited, very low quality evidence
suggested that symptom-specific quality of life scores improvedwhenfluid intakewas reduced, although somepeople reported headaches,
constipation or thirst. A further three trials involving 160 women and nine men compared reduction in caffeinated drinks with no
change, and one trial involving 42 women compared a soy-rich diet with soy-free diet. However, it was not possible to reach any
conclusions about the effects of these changes, due to methodological limitations, that resulted in very low quality evidence.
Adverse effects appeared relatively uncommon for all interventions studied.
All included studies had a high or unclear risk of bias across all bias parameters, but most notably for allocation concealment. The
main factors for our downgrading of the evidence were risk of bias, indirect evidence (less than 12 months of follow-up; and not all
participants having confirmed urinary incontinence at baseline in some studies), and imprecise results with wide confidence intervals.
Other interventions such as reduction in consumption of sweetened fizzy or diet drinks; reduction in alcohol consumption; avoiding
constipation; smoking cessation; restricting strenuous physical forces; or reducing high levels of, or increasing low levels of, physical
activity, could not be assessed in this review, as no evidence from randomized controlled trials or quasi-randomised trials was available.
Authors’ conclusions
Evidence for the effect of weight loss on urinary incontinence is building and should be a research priority. Generally, there was
insufficient evidence to informpractice reliably about whether lifestyle interventions are helpful in the treatment of urinary incontinence.
P L A I N L A N G U A G E S U M M A R Y
Lifestyle interventions for the treatment of urinary incontinence in adults
Background
Urinary incontinence imposes a considerable burden on individuals and on society. Although a range of treatments is available,
alterations in lifestyle are frequently recommended for the treatment of urinary incontinence, as they are relatively low in cost and
have few unwanted side-effects. Advice commonly given includes losing weight, changes in diet, adjusting volume of fluid intake,
decreasing caffeine or alcohol consumption, avoiding constipation and straining (when passing faeces), stopping smoking, and being
more physically active - though restricting excessive heavy activity.
What we wanted to find out
We (a team of Cochrane researchers) wanted to see whether lifestyle interventions have a beneficial effect on any type of urinary
incontinence in adults
What we did
We searched the medical literature extensively up to July 2013 for studies that compared the effects of community-based lifestyle
alterations with either no treatment, or other non-surgical treatments, or medical (medicine) treatment, on urinary incontinence in
adults.
What we found
We identified 11 studies, with 5974 participants (nearly all women, only 20 were men), that investigated the effect of lifestyle alterations
on urinary incontinence. Four investigated weight loss; one compared a soy-rich diet with a soy-free diet; three investigated changes in
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volume of fluid intake; and three investigated the effect of reducing caffeine intake. We identified no trials that investigated reducing
alcohol intake, avoiding constipation and straining, stopping smoking or levels of physical activity.
Findings from four studies suggested that weight loss may reduce incontinence among overweight women and this merits further
research. However, it should be noted that a large proportion of the participants contributing to this result were part of two diabetes
studies that, while they recorded the effect of weight loss on urinary incontinence, did not record how many participants suffered from
it at the start of the study. The duration of the weight loss programmes in these studies ranged from three to 12 months.
A small amount of very low quality evidence from the studies that investigated volume of fluid intake suggested that symptoms of urinary
incontinence may reduce when fluid intake is reduced, although some participants in the studies reported headaches, constipation or
thirst.
We could not combine the findings from other studies that investigated a similar treatment (e.g. caffeine reduction) because they
measured their results in different ways, and/or were of poor quality, which means their results may be unreliable. Much more well-
designed research is needed, so that lifestyle recommendations for the treatment of incontinence can be based on good evidence. At
present there is not enough evidence to establish whether any lifestyle treatments work.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Weight loss compared to control for the treatment of urinary incontinence in adults
Patient or population: adults with urinary incontinence
Settings:
Intervention: weight loss
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Weight loss
Cure rates by patient ob-
servation (all UI types) -
not reported
Not estimable -
Improvement rates by
patient observation (all
UI types)
Follow-up: 6 months
544 per 1000 762 per 1000
(621 to 931)
RR 1.4
(1.14 to 1.71)
304
(1 study)
⊕⊕©©
low1,2
Condition-specific qual-
ity of life
In-
continence Impact Ques-
tionnaire. Scale from: 0 to
400. Better quality of life
indicated by lower values.
Follow-up: 3 months
The median condition-
specific quality of life in
the control groups was
89 points
The median condition-
specific quality of life in
the intervention groups
was
52 lower
(95% CI not estimable)
40
(1 study)
⊕⊕©©
low1,2
Adverse effects
Follow-up: 3 months
Not estimable 48
(1 study)
The study reported that
the intervention had ’few
side effects’
4
L
ife
sty
le
in
te
r
v
e
n
tio
n
s
fo
r
th
e
tre
a
tm
e
n
t
o
f
u
rin
a
r
y
in
c
o
n
tin
e
n
c
e
in
a
d
u
lts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Cure rates by symp-
tom quantification (all UI
types)
Follow-up: 12 months
315 per 1000 350 per 1000
(287 to 431)
RR 1.11
(0.91 to 1.37)
738
(1 study)
⊕⊕©©
low1,3,4
Improvement rates by
symptom quantification
(all UI type)
Follow-up: 12 months
325 per 1000 393 per 1000
(332 to 468)
RR 1.21
(1.02 to 1.44)
1032
(2 studies)
⊕⊕©©
low1,3,4
Prevalence of weekly UI
(all UI type)
Follow-up: 12 months
286 per 1000 252 per 1000
(223 to 286)
RR 0.88
(0.78 to 1)
2739
(1 study)
⊕©©©
very low1,3,4,5
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; UI: urinary incontinence
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias: We downgraded the evidence by one level because blinding of participants and personnel was unlikely.
2 Indirectness: We downgraded the evidence by one level because of short follow-up <12 months
3 Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation
concealment method in one study (Phelan 2012).
4 Missing outcome data in 7%-10% of the participants in one study (Phelan 2012).
− Indirectness: We downgraded the evidence by one level because data include a sub-study of a trial (Phelan 2012) for diabetes that
included continent as well as incontinent patients; only 27% had weekly urinary incontinence at baseline.
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B A C K G R O U N D
Description of the condition
Urinary symptoms pose a considerable health care burden with
200 million people suffering from incontinence worldwide (
Abrams 2005). The Leicestershire Medical Research Council
(MRC) incontinence study, which was the largest comprehensive
study of urinary symptoms in a UK general population, reported
that 29% of men and 34% of women aged 40 years or over ex-
perience clinically significant incontinence or voiding symptoms
(McGrother 2004), with substantial impact on quality of life.
This represents a financial burden to the National Health Service
(NHS) of 1% of its annual budget (Turner 2004). Overall preva-
lence and service needs will continue to grow as the population
ages.
Lifestyle factors may play a role in either in the improvement,
or maintenance, of continence. While published literature about
lifestyle factors and incontinence is sparse (Hannestad 2004), al-
terations in lifestyle are frequently recommended by both health-
care professionals and lay people in the belief that they will de-
crease urine leakage. For example, advice is commonly given to
lose weight, increase or decrease fluid intake, stop using caffeinated
drinks, reduce alcohol consumption, or to be more physically ac-
tive - but restrict excessive heavy activities that put pressure on
the pelvic floor, such as aerobics or lifting - to stop smoking and
avoid constipation and straining. Such recommendations are rarely
based on evidence from clinical trials, but on the basis that there
are plausible explanations for why these changes might work, and
that they are unlikely to cause harm.
Theoretically, the potential for diet and lifestyle to impact upon in-
continence is wider than factors currently identified from a purely
empirical viewpoint. It is generally recognised that nutritional and
metabolic mechanisms impinge upon all systems of the body in-
cluding the urinary tract. In practice, incontinence is more com-
monly observed in patients with specific morbidities such as cere-
brovascular disease, dementia, depression and diabetes, and this
is supported by scientific evidence (McGrother 2007). In these
chronic conditions, diet and lifestyle factors have been identified
as probably causal: for example, high saturated fat, low fatty fish/
omega-3 fat, low fibre, high glycaemic index, low vegetable and
high salt intakes (Chowdhury 2012; He 2006; Baumgart 2015;
Ortega 2012; Skerrett 2010).More generally, theWHOand statu-
tory guidance in the UK and USA currently recognize the impor-
tance of poor diet, physical inactivity, excess alcohol and sugary
drinks plus smoking in the prevention of such chronic conditions.
On this basis, modifications to such diet and lifestyle factors may
prevent or reduce bladder dysfunction.
A wide range of interventions and treatments has been used in the
management of urinary incontinence, including conservative in-
terventions such as physical therapies: a review by Dumoulin and
colleagues broadly supported the recommendation for pelvic floor
muscle training in women (Dumoulin 2010); and Herbison and
colleagues reported that the evidence tentatively supported the use
of vaginal cones in women who find them acceptable (Herbison
2002). In the area of behavioural training, Wallace and colleagues
identified that there was limited evidence on the use of bladder
training (Wallace 2004), but it was unlikely to do harm. The Lipp
2011 review on anti-incontinence devices identified insufficient
evidence for the use of devices and suggested further well designed
trials in the area. The Nabi 2006 review on pharmaceutical in-
terventions, e.g. anticholinergics, reported statistically significant
improvements in symptoms, while for surgical interventions, the
Ogah 2009 review reported that minimally invasive surgery was as
effective as traditional surgery. For absorbent products, Fader and
colleagues identified minimal evidence (Fader 2007; Fader 2008),
although there was sufficient evidence to support the use of some
pads over others. However, this review specifically focuses on the
use of lifestyle interventions for the treatment of urinary inconti-
nence.
Description of the intervention
1) Weight loss
Both obesity and urinary incontinence are common problems in
women andmen.Obesewomenhave higher intra-abdominal pres-
sure than non-obese women, and it is thought that this chroni-
cally elevated pressure may predispose to incontinence by weak-
ening pelvic floor support structures. In recent years, a number
of trials (Hunskaar 2008; Subak 2002; Subak 2009a) including
three which specifically reported on weight loss by obese or over-
weight adults compared to no treatment (Brown 2006a; Subak
2005a; Subak 2009b) have reported an association between in-
creased weight and urinary incontinence.
2) Dietary factors
Dietary factors are recognised as contributing to the maintenance
of good health, which is strongly related to low levels of inconti-
nence (McGrother 2007). Indications from epidemiological data
suggest that poor diet may play a specific role in urinary inconti-
nence. The prospective Leicestershire MRC Incontinence Study,
which examined food items and nutrients in relation to incidence
of urinary incontinence, found associations between 1) stress uri-
nary incontinence and low intake of bread plus high saturated fat,
zinc and Vitamin B12, and 2) overactive bladder and low intakes
of bread, vegetables, chicken, protein, vitamin D and potassium in
women (Dallosso 2003; Dallosso 2004a; Dallosso 2004b). Over-
active bladder was associated only with high potato intake in men
(Dallosso 2004c). The ratio of high saturated fat to polyunsatu-
rated fat intake has also been related to the severity of incontinence
in women (Maserejian 2010).
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3) Fluids
Worsening of urinary urgency, frequency and incontinence is of-
ten reported after consuming caffeine, alcohol, fizzy (carbonated)
drinks, sweetened diet drinks (Cartwright 2007), or excessive flu-
ids. In a large prospective cohort study, fizzy drinks was the only
type of fluid intake independently associated with incontinence in
women (Dallosso 2003), whereas in men, beer intake appeared to
be protective (Dallosso 2004c). In a study of urinary symptoms
in younger men, caffeine, exercise and tobacco were all associated
withworse symptoms in the lower urinary tract (Moon 1997).Caf-
feine may increase bladder muscle contractility (Creighton 1990),
whereas alcohol or excessive fluids may have a diuretic effect, while
it has been hypothesised that some sweeteners lead to increased
detrusor overactivity (Dasgupta 2006). Sugary fizzy drinks have a
high glycaemic index, which worsens control of diabetes and re-
lated neuro-muscular functions. These factors are also recognised
as potential hazards to general health, which is predictive of uri-
nary incontinence.
4) Constipation and straining
Some evidence suggests that the chronic straining associated with
constipation may be a risk factor in the development of urinary
incontinence (Moller 2000), and may increase the latency time of
the pudendal nerve (Kiff 1984). This nerve supplies the muscles
responsible for pelvic support, which is why it has been suggested
that constipation may result in, or worsen, urinary incontinence.
Poor diet and lack of fibre in the diet can also lead to constipation.
5) Smoking cessation
Several trials have suggested that smokers are more likely than
non-smokers to report urinary incontinence (Dallosso 2003;
Tampakoudis 1995).
6) Physical activity
Prospective cohort evidence suggests that moderate physical ac-
tivity decreases the risk of onset of urinary incontinence in mid-
dle-aged and older women (Danforth 2007; McGrother 2012;
Townsend 2008).
7) Physical forces
It is likely that weakened pelvic floor support structures and raised
intra-abdominal pressure caused by heavy lifting and strenuous
activity such as aerobics may affect incontinence. Strenuous activ-
ity alone may also lead to incontinence in the short term (Nygaard
2006).
Why it is important to do this review
This review aimed to evaluate the effects of these types of lifestyle
interventions on improving incontinence and related symptoms
by assessing the evidence available from randomized controlled
trials. Such interventions are cheap to deploy, have few side effects,
are broadly acceptable andmay improve the overall health of adults
with and without urinary incontinence. This review will enable us
to better understand the effect such interventions have on urinary
incontinence.
O B J E C T I V E S
The objective of the review was to determine the effectiveness of
specific lifestyle interventions (i.e. weight loss; dietary changes;
fluid intake; reduction in caffeinated, carbonated and alcoholic
drinks; avoidance of constipation; stopping smoking; and physical
activity) in the management of adult urinary incontinence (UI).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials or quasi-randomised trials (that use some as-
signment rule such as alternation, or hospital or clinic record num-
ber).
Types of participants
Adults with urinary incontinence, diagnosed either by symptom
classification (stress UIurinary incontinence (SUI); urgency uri-
nary incontinence (UUI); mixed urinary incontinence (MUI))
or by urodynamic investigation (urodynamic stress incontinence
(USI); idiopathic detrusor overactivity (IDO)). Due to the small
number of studies available, we made a pragmatic decision af-
ter the review commenced, to include all studies if some of the
participants had UI. An example would include studies primarily
concerned with people with overactive bladder (OAB): OAB de-
scribes a clinical problem - that encompasses urgency and urgency
UI (usually with frequency and nocturia) - from a symptomatic
perspective (Abrams 2002). The review excluded studies where
all participants explicitly had overactive bladder without UI (so-
called ’OAB-dry’). Otherwise we included studies with overactive
bladder with the assumption that some participants (regardless of
the proportion) had UI (so-called ’OAB-wet’). We also made the
post hoc decision to include studies that reported prevalence of UI
as an outcome. Here the identified studies were fromdiabetes trials
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where not all participants had UI at baseline. Given that obesity is
amongst the most clearly established risk factors for UI in women
(Abrams 2013), we assumed that some study participants had UI
at baseline. We excluded studies where all participants were con-
tinent at baseline.
Types of interventions
One arm of the trial had to be allocated to a community-based
lifestyle intervention following a standardised (within trial) proto-
col. Any of the following lifestyle interventions alone or in com-
bination were included: advice given to lose weight, change diet,
adapt the amount or type (e.g. caffeine) of fluid intake, and mod-
erate alcohol consumption, as well as advice given to avoid consti-
pation and straining, stop smoking, and be more physically active
whilst restricting excessive heavy physical activity.
Comparison interventions included no (active) treatment, other
conservative physical therapies such as pelvic floor muscle training
(PFMT) or bladder training, or pharmacological therapies.
We did not consider interventions such as leaflet-only lifestyle
advice, without a standardised (within trial) protocol, to be eligible
active treatments.
Types of outcome measures
The International Continence Society recommends five out-
come categories: the individual’s observation (reported symp-
toms), quantification of symptoms (urine loss), the clinician’s ob-
servation, and quality of life outcomes, namely, condition-specific,
and generic and socioeconomic measures (Mattiasson 1998).
Primary outcomes
• Individual report of symptom cure/improvement.
• Condition-specific quality of life, e.g. ICIQ-Urinary
Incontinence Form (Avery 2004).
• Adverse effects.
Secondary outcomes
• Quantification of symptoms (e.g. diary, bladder chart):
◦ cure and improvement rates on diary or pad test in the
short term (less than 12 months) and longer term (more than 12
months);
◦ number of incontinent episodes in 24 hours.
• Generic quality of life measures e.g. Short Form 36 (Ware
1993).
• Socio-economic measures:
◦ costs of interventions;
◦ cost-effectiveness of interventions;
◦ resource implications.
• Non-specified outcomes judged important when
performing the review. As the search identified trials in people
with diabetes that reported prevalence of UI at follow-up, post
hoc decisions were made to include prevalence as an outcome
only for the assessment of weight loss interventions.
Main outcomes for ’Summary of findings’ table
Main outcomes for the ’Summary of findings’ table were (in order
of importance):
• symptom cure based on individual report;
• symptom improvement (including cure) based on
individual report;
• condition-specific quality of life;
• adverse effects;
• symptom cure based on quantification of symptoms;
• symptom improvement (including cure) based on
quantification of symptoms;
• number of incontinent episodes in 24 hours.
For the assessment of weight loss interventions only, prevalence
at follow-up was included in place of the number of incontinent
episodes. Main outcomes for weight loss interventions thus were
(in order of importance):
• symptom cure based on individual report;
• symptom improvement (including cure) based on
individual report;
• condition-specific quality of life;
• adverse effects;
• symptom cure based on quantification of symptoms;
• symptom improvement (including cure) based on
quantification of symptoms;
• prevalence of UI at follow-up.
The timeframe chosen for these outcomeswas at 12-month follow-
up.
Search methods for identification of studies
We did not impose any language or other restrictions on the
searches.
Electronic searches
This review drew on the search strategy developed for the
Cochrane Incontinence Group. We identified relevant trials from
the Cochrane Incontinence Group Specialised Trials Register. For
more details of the search methods used to build the Specialised
Register please see the Group’s module in The Cochrane Library.
The register contains trials identified from the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), MEDLINE, and
MEDLINE in process, and handsearching of journals and confer-
ence proceedings. Most of the trials in the Cochrane Incontinence
Group Specialised Register are also contained in CENTRAL. The
date of the search was 3 July 2013; the results of these searches are
fully incorporated into the review.
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We completed an additional search of ClinicalTrials.gov on 28
November 2013 - this search is detailed in Appendix 1. The results
of this search have not been fully incorporated into the review -
we have placed potentially eligible studies into Studies awaiting
classification.
We undertook a further updated search of the Specialised Register
on 27 October 2014 the results of which we assessed, and added
potentially eligible studies to Studies awaiting classification (the
Specialised Register now includes searches of ClinicalTrials.gov
and WHO ICTRP).
The terms used to search the Incontinence Group Specialised Reg-
ister were:
(({DESIGN.CCT*}
OR {DESIGN.RCT*}) AND ({INTVENT.LIFESTYLE*}) AND
{TOPIC.URINE.INCON*})
(All searches were of the keyword field of Reference Manager
2012).
Searching other resources
We searched the references lists of relevant articles.
Data collection and analysis
Selection of studies
Two review authors independently screened eligible studies for
inclusion. We resolved any disagreements by discussion. We listed
excluded trials with reasons for their exclusion.
Data extraction and management
Two review authors extracted data from published reports inde-
pendently,and resolved any disagreements by discussion. Where
there was insufficient information in the published report, we
planned to seek clarification from the trialists, but this was not
required.
For studies where not all participants had UI at baseline, we pre-
ferred the data from a subgroup of people with UI, if these were
reported separately. If such data were not available, we extracted
data from the whole study but recorded the proportion of people
with UI at baseline where possible.
Assessment of risk of bias in included studies
Two review authors evaluated all relevant studies independently
for their potential risk of bias.
We undertook assessment of methodological quality using the
Cochrane ’Risk of bias’ tool to include assessment of: random se-
quence generation; allocation concealment; blinding of partici-
pants and personnel; blinding of outcome assessment; incomplete
outcome data; selective reporting; and other sources of bias. We
resolved any differences of opinion related to the ’Risk of bias’ as-
sessment by discussion. We planned sensitivity analysis using only
the data from studies having a low risk of bias, but this was not
possible due to lack of data.
Measures of treatment effect
We undertook quantitative synthesis if we identified more than
one eligible study.We used a fixed-effect model to calculate pooled
estimates of treatment effect across similar trials with their 95%
confidence intervals. We combined dichotomous outcome data
using the relative risk (RR) method.We intended to combine con-
tinuous outcomes using the Mantel-Haenszel weighted mean dif-
ference (WMD) method, but this was not done because the con-
tinuous outcome data available were either not reported as means
with standard deviations (SD), or were not reported by more than
one study. We calculated a mean difference for individual trials
where possible.
We grouped trial data according to the type of incontinence when
data were available. We planned other subgroup analyses (e.g. age,
gender, severity of symptoms, methodological quality), but could
not perform these due to insufficient data.
We did not perform quantitative synthesis for adverse events, be-
cause the included studies reported adverse events narratively and
very few numerical data were available; instead we report the find-
ings by a qualitative summary.
Unit of analysis issues
We analyzed trials with a parallel group design on the basis of
individuals randomized.
The recommended approach for including cross-over trials in a
meta-analysis is to perform a paired analysis taking into account
the within-person differences (Elbourne 2002). However, the in-
cluded cross-over trials tended to report all measurements after
the active treatment period and all measurements after the control
treatment period, and then compared these data as if they came
from a parallel group trial. The trials also did not publish themean
and standard deviation values (for the within-person differences)
required to perform paired analyses. We therefore presented data
from these trials as reported, although this gives rise to a ’unit of
analysis’ error. These results should therefore be interpreted with
caution.
Dealing with missing data
Where possible, we used data based on explicit intention-to-treat
analysis. If this was unclear, we performed available case analysis.
We collected data on dropout rates, and noted reasons for with-
drawal and dropout reported by the trialists in the ’Characteristics
of included studies’ table when these appeared to be treatment-
related.
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Assessment of heterogeneity
We assessed heterogeneity across studies by visual inspection of
plots of the data, the Chi² test for heterogeneity, and the I² statistic
(Higgins 2003).We also explored potential sources of heterogene-
ity.
Assessment of reporting biases
We planned to create funnel plots of the intervention effect
estimates against their standard errors using Review Manager
(RevMan; RevMan 2014), but the number of studies included in
the review was not sufficient for us to perform this assessment.
Sensitivity analysis
To assess the potential impact of widening the inclusion criteria of
the review to include studies where not all of the participants had
UI at baseline, we considered conducting sensitivity analyses in
which wewould exclude studies withmixed populations (with and
without incontinence) from the meta-analysis of each outcome,
however, we could not do this due to the low number of studies
available.
Summary of findings table
We summarised results in ’Summary of findings’ tables, follow-
ing the standard methods described in Chapters 11 and 12 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011a; Schünemann 2011b). As the recommenda-
tion to generate ’Summary of findings’ tables is relatively new and
became prominent after the publication of the review protocol,
we decided to undertake this exercise and determined main out-
comes for these tables during the course of the review. We used no
external information in the ’Assumed risk’ column of the tables.
The overall quality of evidence for each outcome was assessed us-
ing the GRADE (Grading of Recommendations Assessment, De-
velopment and Evaluation) approach (Guyatt 2008). In GRADE,
there are four levels of quality of evidence: high, moderate, low
and very low. Randomised studies begin as ‘high’ quality evidence,
but may be rated downwards depending upon performance in one
or more of five pre-defined categories: (i) limitation of study de-
sign (risk of bias), (ii) inconsistency (heterogeneity), (iii) indirect-
ness, (iv) imprecision, and (v) other considerations (e.g. publica-
tion bias).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The electronic searches retrieved a total of 338 records, fromwhich
we obtained 60 full text articles we assessed for eligibility. We con-
sidered 32 reports of 11 trials eligible for inclusion in the review,
and identified one report of an eligible ongoing trial (Moholdt
2011).
Additionally, we completed assessment of 1151 records retrieved
fromClinicalTrials.gov (28November 2013) after themain search
was fully incorporated into the review - details of four potentially
relevant records are given in the Characteristics of studies awaiting
classification table (Baker 2011; Heesakkers 2009; Huang 2012;
Markland 2013). A further updated search of the Specialised Reg-
ister on 27 October 2014 retrieved 101 records; we screened these
and added three extra studies to the Studies awaiting classification
section (Gozukara 2014; Seckin 2011; Wells 2014). The results
of these latter two searches (ClinicalTrials.gov and the Specialised
Register) have not been fully incorporated into the review. The
flow of literature through the assessment process is shown in the
PRISMA flowchart (Figure 1).
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Figure 1. PRISMA study flow diagram
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Included studies
Design
The review included a total of 32 reports of 11 trials: five paral-
lel-arm randomized controlled trials (RCTs; Brown 2006b; Dowd
1996; Phelan 2012; Subak 2005; Subak 2009), four random-
ized cross-over trials (Hashim 2008; Manonai 2006; Swithinbank
2005; Wells 2011), and one quasi-randomised trial that used
health record numbers as the basis for assigning people to inter-
ventions (Bryant 2002). We also identified one unpublished RCT
with limited information (Miller 2007).
Participants
The included trials involved a total of 5974 participants, who were
predominantly female (5954 women and 20 men). The average
age (it was unclear if this was amean ormedian) of the participants
in the included trials ranged from 49 to 58 years, except for two
trials with means of 62.7 years (Hashim 2008), and 70.25 years
(Dowd 1996).
Sample size varied across trials. The majority of included trials
had 60 or fewer participants (seven trials), however, two trials had
more than 1000 participants and a further two trials had more
than 100 participants Brown 2006b; Phelan 2012; Subak 2009;
Swithinbank 2005).
In four trials, all trial participants had UI at baseline:
• Dowd 1996: 58 women with UI;
• Subak 2005: 48 women with SUI (6%), stress predominant
MUI (40%), UUI (11%) and urgency predominant MUI (43%);
• Subak 2009: 338 women with SUI (8%), stress
predominant MUI (25%), UUI (18%) and urgency
predominant MUI (48%);
• Swithinbank 2005: 110 women with USI (57%) and IDO
(43%).
Four trials included adults with OAB, leading to UUI in some of
the trial participants:
• Bryant 2002: 9 men and 86 women with symptoms of
urgency, frequency and/or UUI; 83% had UUI at baseline;
• Hashim 2008: 11 men and 13 women with OAB; 29% had
UUI at baseline;
• Miller 2007: 60 women with OAB;
• Wells 2011: 14 women with OAB, with or without UI.
One trial included women with urogenital atrophy, leading to UI
in some of the participants:
• Manonai 2006: 42 women with urogenital atrophy; 61%
had SUI and 19% had UUI at baseline.
The other trials that contributed the largest numbers of partici-
pants were sub-studies of large diabetes trials of intensive weight
loss programmes, namely the DPP (Diabetes Prevention Program;
Brown 2006b), which focused on the prevention of diabetes, and
Look AHEAD (Action For Health in Diabetes; Phelan 2012),
which evaluated cardiovascular morbidity and mortality among
individuals with type 2 diabetes. Not all of the trial participants
in these trials had UI at baseline, but reported prevalence of UI at
follow-up:
• Brown 2006b: 2191 women in a diabetes trial; no baseline
measures of UI;
• Phelan 2012: 2994 women in a diabetes trial; 27% had
weekly UI at baseline.
Interventions
Weight loss
Four trials assessed the effect of weight loss programmes on in-
continence compared with a control intervention (Brown 2006b;
Phelan 2012; Subak 2005; Subak 2009). All weight loss interven-
tions included components of diet and physical activity.
Diet
The review identified one trial that examined dietary factors by
comparing a soy-rich diet with a control diet (Manonai 2006).
Changing volume of fluid intake
Three trials assessed the effect of changing the volume of fluid
intake (Dowd 1996; Hashim 2008; Swithinbank 2005).
Type of fluid intake
Three trials assessed the effect of reducing caffeinated drinks (
Bryant 2002; Miller 2007; Wells 2011). No relevant trials were
identified with respect to alcohol, sweetened fizzy drinks or diet
drinks.
Constipation and straining, smoking cessation, physical
activity and physical forces
The review identified no randomized trials addressing the effect
of constipation and straining, smoking cessation, physical activity
or physical forces on urinary incontinence.
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Outcome
Quality of reporting of outcomes was generally poor. Not all spec-
ified outcomes were reported. Where reported, outcomes were re-
ported using diverse measures, which made the results difficult to
interpret.Meta-analysis was performed only for cure and improve-
ment rates and UI prevalence from the weight loss interventions.
All other outcomes were summarised narratively.
Excluded studies
We excluded 27 reports relating to 20 studies after full text screen-
ing; see Characteristics of excluded studies. For example, the re-
view excluded studies where lifestyle change was implemented as
part of a multi-faceted intervention, e.g. dietary change and con-
stipation management with pelvic floor muscle training, because
in such studies we could not separate the effects of lifestyle change
from other factors.
Risk of bias in included studies
The risk of bias of the included trials is summarised in Figure 2
and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Four of the 11 included trials described adequate methods of
random sequence generation (Brown 2006b; Subak 2005; Subak
2009; Wells 2011), and of these, allocation was adequately con-
cealed in two (Subak 2005; Subak 2009), but was unclear in the
other two (Brown 2006b; Wells 2011). One trial used quasi-ran-
domisation based on health record numbers and was therefore
at high risk of selection bias (Bryant 2002). Other trials did not
describe the methods used for random sequence generation and
allocation concealment and so we judged them to be at unclear
risk of bias for this domain.
Blinding
Blinding of participants and personnel was not feasible due to
the nature of interventions; this may have biased self-reported
outcomes such as cure, improvement and quality of life. Blinding
of outcome assessment should be possible, but was done in only
three trials (Phelan 2012; Subak 2005; Subak 2009), and was
unclear in the others.
Incomplete outcome data
The percentage of participants followed up and included in anal-
ysis varied across trials as shown below:
• 100% (Hashim 2008);
• 90% or more (Phelan 2012);
• between 80% and 89% (Brown 2006b; Manonai 2006;
Subak 2005; Subak 2009; Swithinbank 2005);
• between 70% and 79% (Bryant 2002; Wells 2011);
• 55% (Dowd 1996); and
• not reported (Miller 2007).
Of these, four trials were considered to be at low risk of attrition
bias (incomplete outcome data) because the trial reports stated
that either there were no missing outcome data (Hashim 2008), or
described use of imputation (Subak 2009), or confirmation that
participantswithmissingdata did not differ fromparticipants with
data in terms of demographic and clinical characteristics (Brown
2006b; Subak 2005). One trial (Dowd 1996), in which 26 (45%)
of the 58 participants did not complete diaries and were excluded
from analysis, was assessed as having a high risk of attrition bias.
Reasons for missing outcome data were not clearly described in the
other trials, and it was difficult to determine whether the extent
of missing data was likely to induce clinically important bias. We
therefore judged them to be at unclear risk of bias for this domain.
Selective reporting
All trials reported on the outcomes listed in their methods sec-
tion but, as there was otherwise insufficient information to permit
judgement of low or high risk of bias within published reports, we
consider them to be at unclear risk of bias for this domain.
Other potential sources of bias
Two trials assessing fluid intake manipulation (Dowd 1996;
Hashim 2008), and caffeine reduction (Miller 2007; Wells 2011),
noted that compliance to the trial protocol was relatively poor.
Apart from this factor, it was difficult to assess whether any other
important risk of bias existed in these and the other trials.
Effects of interventions
See: Summary of findings for the main comparisonWeight loss
compared to control for the treatment of urinary incontinence in
adults; Summary of findings 2 Soy-rich diet compared to control
for the treatment of urinary incontinence in adults; Summary of
findings 3Decreasing fluids compared to increasing fluids for the
treatment of urinary incontinence in adults;Summary of findings
4 Caffeine reduction compared to control for the treatment of
urinary incontinence in adults; Summary of findings 5 Lifestyle
weight loss compared to metformin weight loss for the treatment
of urinary incontinence in adults
The results of the included studies, and the quality of the body of
evidence for each outcome, are summarised in the ’Summary of
findings’ tables (Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4; and Summary of findings 5).
1) Weight loss by obese or overweight adults versus no
active intervention
Description of studies
We identified four trials involving a total of 4701 participants that
compared intensive lifestyle weight loss interventions with control
or no active interventions in relation to incontinence (Brown
2006b; Phelan 2012; Subak 2005; Subak 2009). All participants
in two of the included trials had UI (Subak 2005; Subak 2009).
The other two trials were sub-studies of large diabetes trials (Brown
2006b; Phelan 2012), DPP and Look AHEAD, respectively, and
contributed 4315 (92%) of the trial participants to the analysis.
These trials did not recruit participants specifically with UI and
therefore not all the participants had it.We extracted outcome data
on cure and improvement (based on quantification of symptoms)
from a subgroup of people with UI in the Look AHEAD trial
(N = 738; Phelan 2012), and data on prevalence of UI at follow-
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up from the whole (sub-)study (N = 2994). The trial authors
reported the one-year results of a four-year intensive weight loss
programme; the trialists planned that follow-up of this trial would
run until 2014. The only relevant outcome from theDPP trial was
prevalence at follow-up of UI from the whole (sub-)study (N =
1321; Brown 2006b); the proportion of people with UI at baseline
was unknown (not reported).
All participants in the included trials were female. The weight loss
groups were given a reduced-calorie diet and increased physical
activity according to a structured and supervised protocol. The
comparison groups received:
• no intervention (waiting list; Subak 2005);
• a structured education programme on weight loss (Subak
2009);
• diabetes support and education (Phelan 2012); or
• a placebo drug (Brown 2006b).
Duration of the interventions varied across trials. The intensive
intervention phase lasted for:
• three months (Subak 2005);
• six months followed by a further randomisation in the
intervention group (not the control group) to motivation-based
or skill-based maintenance programmes for an additional 12
months (Subak 2009);
• six months with monthly follow-up thereafter for an
average of 2.8 years (Brown 2006b); or
• 12 months (Phelan 2012).
All four trials reported that women allocated to the intervention
group achieved a statistically significant decrease in body weight
from baseline compared with those in the control group.
Primary outcomes
Improvement rates based onwomen’s perception (self-report) were
reported in one trial (Subak 2009). The results showed that at
six months women in the intervention group were more likely to
report improvement than those in the control group at six months
(163/214 (76%) versus 49/90 (54%), risk ratio (RR) 1.4, 95%
confidence interval (CI) 1.14 to 1.71; Analysis 1.1), 12 months
(298 women in analysis, 75% versus 68%, RR not estimable,
reported P value 0.2) and 18 months (291 women in analysis,
75% versus 62%, RR not estimable, reported P value 0.02) after
randomisation (Analysis 1.2). The reported P values suggest that
the differences were statistically significant at six months and 18
months. No information was available on self-reported cure.
The intervention group also reported that incontinence had less
adverse impact on their lives (median Incontinence Impact Ques-
tionnaire scores, 40 women in analysis, 37 versus 89, P value 0.01)
and was less distressing (median Urogenital Distress Inventory
scores, 40 women in analysis, 104 versus 195, P value < 0.0001)
compared with the control group in one trial that reported these
outcomes (Subak 2005; Analysis 1.3).
Adverse effects appeared to be relatively uncommon, with one trial
reporting that the intervention had ’few side effects’ (Subak 2005).
Secondary outcomes
Three trials reported cure and improvement rates based on quan-
tification of symptoms (rather than women’s perception; Subak
2005; Subak 2009; Phelan 2012; Analysis 1.4; Analysis 1.5;
Analysis 1.6; Analysis 1.7). Depending on the trial, length of fol-
low-up and type of incontinence, cure rates for the intervention
group ranged from 7% to 35% and improvement rates ranged
from 37% to 64%. In the control group cure rates ranged from0%
to 32% of women, while improvement ranged from 0% to 62%.
In general the intervention group had higher rates in terms of both
cure and improvement compared with the control group when
stress and urgency UI symptoms were considered together (’all
UI’). For improvement rates, the difference between the groups
was statistically significant at three months (7/19 (37%) versus 0/
21 (0%), RR 16.50, 95% CI 1.01 to 270.78; Analysis 1.6), six
months (88/214 (41%) versus 20/90 (22%), RR 1.85, 95% CI
1.22 to 2.81; Analysis 1.6) and 12 months (234/583 (40%) versus
146/449 (32%), RR 1.21, 95% CI 1.02 to 1.44; Analysis 1.6),
although the effect was attenuated over time and was no longer
statistically significant at 18 months (91/197 (46%) versus 36/90
(40%), RR 1.15, 95% CI 0.86 to 1.55; Analysis 1.6). The differ-
ence for cure rates did not reach statistical significance (Analysis
1.4).
Looking at different types of UI at each outcome time point,
the Subak 2009 trial showed a similar pattern with a tendency
towards greater improvement in the intervention group than in
the control group among the subgroup of women who reported
stress symptoms at six, 12 and 18 months (P values 0.01, 0.01 and
0.92 , respectively) or urgency symptoms at six, 12 and 18 months
(P values 0.04, 0.07 and 0.03, respectively; Analysis 1.7). In the
same trial, cure rates by type of UI also favoured the intervention
group for both SUI (P value 0.004) and UUI (P value 0.02) at six
months, but no further follow-up was available (Analysis 1.5).
The prevalence of weekly (or more frequent) UI of any type (stress
or urgency) was lower in the intervention group than in the control
group in the two sub-studies of diabetes trials with a follow-up of
between one and 2.8 years (Analysis 1.8). According to adjusted
odds ratios (ORs) reported by trial authors, the intervention was
associated with a statistically significant reduction in the odds of
having UI by around 20% to 24% compared with the control
group (in Phelan 2012, adjusted OR 0.80, 95% CI 0.65 to 0.98;
in Brown 2006b, adjusted OR 0.76, 95% CI 0.61 to 0.95). The
prevalence of weekly SUI was also lower in the intervention group
compared with the control in both trials (in Phelan 2012, adjusted
OR 0.73, 95% CI 0.55 to 0.96, Analysis 1.9; in Brown 2006b,
adjusted OR 0.80, 95% CI 0.64 to 1.01) but no such difference
was apparent for UUI (Analysis 1.9). The trial authors suggest
that the reduction in the prevalence of overall weekly incontinence
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may be due to differences in weekly SUI.
Compared with women in the control group, those in the inter-
vention group had a greater percentage reduction from baseline
in weekly incontinence episodes over the period of three to 18
months regardless of type of UI (all, stress or urgency; Analysis
1.10; Analysis 1.11).Differences between the groups for all UI and
SUI episodes were reported to be statistically significant at three,
six and 12 months but no longer significant at 18 months. The
difference for UUI was not statistically significant at any point in
time after three months.
General health-related quality of life was measured only in one
small trial with 40 participants using SF-36 ( (Subak 2005;
Analysis 1.3). The median SF-36 Physical Component Score
favoured the intervention group (55 versus 47, P value 0.003)
but there was no significant difference between the groups in the
Mental Component Score of the same instrument (48 versus 51,
P value 0.09).
2) Dietary changes versus no active intervention
Description of study
We identified only one small trial that assessed the effect of dietary
factors on UI (Manonai 2006). The trial used a randomized cross-
over design and compared a soy-rich diet with a control (soy-free)
diet in 42womenwho experienced at least one of urinary or genital
symptoms owing to urogenital atrophy. At baseline around 61%
and 63%ofwomen in the intervention and control groups, respec-
tively, had SUI episodes and 19% and 11%, respectively, had UUI
episodes. Partcipants underwent two two-week treatment periods
in random order with two four-week washout periods before and
between treatments. The trial authors found compliance to the
diet to be satisfactory on the basis of the elevation of serum levels
of daidzein and genistein during the soy-rich diet period. Out-
come data were available for 36 women who completed the trial.
As data subgrouped by incontinence status were not available, the
extracted data were from the whole study.
Primary outcomes
The trial did not address self-reported cure and improvement rates,
condition-specific quality of life and adverse effects.
Secondary outcomes
The trial did not address cure and improvement rates based on
quantification of symptoms, number of UI episodes and generic
quality of life. The available data suggest that the percentage of
women with UUI episodes in the control group increased from
baseline during the control diet period (N = 36, from 11% to
22%, P value not reported; Analysis 2.1). Correspondingly, symp-
tom scores (mean, SD) of UUI significantly increased during the
control diet period (N = 36, from 0.14 (0.35) to 0.25 (0.50), P
value < 0.05; Analysis 2.2), although the difference was small.
3) Change in fluid intake versus no treatment
Description of studies
We identified three trials that examined altering the level of fluid
intake (Dowd 1996; Hashim 2008; Swithinbank 2005).
One RCT allocated 58 women with UI to one of three groups that
increased fluid intake by 500 (Dowd 1996). The trial provided
a five-week programme with randomisation in the second week.
The trial reported that adherence to the fluid manipulation was
poor, which made results difficult to interpret.
Another randomized cross-over trial with 84 women with UI re-
ported outcome data for the 69 women (39 with USI and 30
with IDO) who completed the trial (Swithinbank 2005). The trial
lasted four weeks. In the first week participants drank normally
(week 1, baseline) and in the second week drank normally, but
only caffeine-free fluids (week 2, caffeine-free baseline). Partici-
pants were then randomized in the order in which they either in-
creased fluids to 3 litres daily, or decreased fluids to 750ml daily, in
the third and fourth weeks while maintaining caffeine restriction
(i.e. only drinking caffeine-free fluids). Adherence to fluid intake
protocols seemed fair, with a mean fluid intake of 1639 ml for
Week 1, 1630 ml for Week 2, 2673 ml for the week of increasing
fluids and 872 ml for the week of decreasing fluids.
In another cross-over trial with 24 participants (11 men and 13
women) with OAB (Hashim 2008), only seven (29%) partici-
pants had UUI at baseline. Participants were randomized into two
groups and asked to either increase or decrease their fluid intake
from baseline. As outcome data specific to a subgroup of people
with UI were not reported separately, the extracted data applied to
the whole study. Group I was asked to drink at < 25% of baseline
for four days, followed by two days’ normal drinking, four days’ at
< 50%, two days’ normal drinking, four days at > 25%, two days’
normal drinking, and then four days at > 50%. Group II did the
reverse. The trial reported that participants had difficulty in either
increasing or decreasing fluids by 50%.
Primary outcomes
One cross-over trial assessed quality of life using the Bristol Fe-
male Lower Urinary Tract Symptoms questionnaire (Swithinbank
2005). Quality of life improved when fluid intake was decreased
compared with baseline in women with USI (N = 39, P value <
0.003) or IDO (N = 30, P value < 0.003) but the women reported
no significant difference in the impact of incontinence symptoms
on their daily life before and after treatment (no further data were
available).
Regarding adverse effects, the same cross-over trial reported that,
with decreasing fluids, ‘side effects such as constipation and thirst
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were troublesome’ (Swithinbank 2005). Another cross-over trial
with 24 participants reported that adverse events observed were
mild and tolerable: four participants felt thirsty and two had
headaches, constipation or concentrated urine when fluid intake
was decreased by 50% from baseline; and one had headache when
intake was reduced by 25% (Hashim 2008).
No information was available regarding self-reported cure or im-
provement.
Secondary outcomes
The number of daily incontinent episodes was reported by three
trials that used different measures. A four-week cross-over trial
stratified results by type of UI at baseline (Swithinbank 2005;
Analysis 3.1). Among 39 women with USI, the week of decreasing
fluid intake (with caffeine restriction) was associated with a statis-
tically significant reduction in the median number of daily incon-
tinent episodes compared with the week of increasing fluid intake
(with caffeine restriction; 0.5 versus 0.7, P value 0.006). Daily in-
continent episodes after decreasing fluid intake (with caffeine re-
striction) were also statistically significantly fewer compared with
the baseline week when participants drank normally (week 1, 0.5
versus 1.6, P value 0.006), but there was no significant difference
when compared with the caffeine-free baseline week in which par-
ticipants maintained a similar fluid intake from baseline, but sub-
stituted caffeine-free drinks for caffeine-containing drinks (week
2, 0.5 versus 0.8, P value 1.000). The week of increasing fluid
intake (no caffeine) did not differ significantly from the caffeine-
free baseline week (week 2, 0.7 versus 0.8, P value 0.426) in terms
of daily incontinent episodes. For 30 women with IDO, drinking
less fluid (no caffeine) had no statistically significant effect on daily
incontinent episodes (0.5 versus 0.6, P value not significant) when
compared with the caffeine-free baseline, but drinking more fluid
(no caffeine) resulted in a significant worsening (increase) of the
symptom (1.1 versus 0.6, P value < 0.003).
In the other cross-over trial participants were asked to increase
or decrease their fluid intake by 25% and 50% from baseline in
random order (Hashim 2008). There was no statistically signifi-
cant difference in the mean number of daily incontinent episodes
between the baseline period and each of the fluid manipulation
periods, although it should be noted that only seven (29%) of the
24 participants had UUI at baseline (Analysis 3.2).
The Dowd 1996 trial randomized participants to three groups
(maintain, increase or decrease fluid), but the authors reported
that adherence to the fluid manipulation protocol was poor and
that results were inconclusive (Analysis 3.3).
4) Caffeine reduction versus continued caffeine intake
Description of studies
We identified three trials that assessed the effects of a reduction in
caffeine intake on incontinence (Bryant 2002; Miller 2007; Wells
2011).
In Bryant 2002, 95 participants (86 women, 9 men) with OAB
(83% had UUI at baseline) were randomized by use of health
record numbers (quasi-randomised) to caffeine reduction edu-
cation or control (continued caffeine intake). In addition, both
groups received bladder training and were followed up for four
weeks. Caffeine intake in the intervention group was reduced sig-
nificantly from baseline compared with the control group (58%
versus 11%, P value < 0 000.1)
Wells 2011 was a randomized cross-over trial in which 14 women
with OAB (with or without UI) underwent two two-week periods
of caffeinated or caffeine-free fluids intake with a 14-day washout
period between treatments. It was a feasibility trial and identified
only in abstract form. Data were available for the 11 women who
completed the trial. Two participants did not comply with caffeine
substitution.
The third trial, Miller 2007, was an unpublished two-arm RCT
that evaluated the effect of restricting ’irritating’ beverages (caf-
feinated or non-caffeinated). In this trial around 60 women with
OAB (it was unclear if some or all participants were incontinent)
were asked to substitute ’irritating’ beverages with milk or water,
but to maintain a similar volume of fluid from baseline. The re-
quest to stop drinking irritating beverages was associated with an
improvement in OAB symptoms, but the trial author noted that
the findings were confounded by a significant reduction in overall
fluid intake in the intervention group from baseline (email com-
munication from the trial author to the Cochrane Incontinence
Group). No further information was available regarding this trial.
The remainder of this section therefore focuses on the first two
trials.
In all three trials, outcome data were extracted from the whole
study, as data specific to the UI subgroup of the trial population
were not reported separately.
Primary outcomes
The Wells 2011 trial reported condition-specific quality of life
using ICIQ Overactive Bladder (ICIQ-OAB) and ICIQ Overac-
tive Bladder Symptoms Quality of Life (ICIQ-OABqol) question-
naires among 11 of the 14 women who completed the trial. Over-
all, women had lower (better) scores during the period of caffeine
substitution (when drinking caffeine-free fluids) compared with
the caffeine exposure period, but the difference in total scores for
the ICIQ-OABqol was not statistically significant (mean 54 versus
68, P value 0.065; Analysis 4.1). No information was available
regarding self-reported cure and improvement, or adverse effects.
Secondary outcomes
There was no evidence of a difference in incontinence episode
frequency between the caffeine reduction and caffeine exposure
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groups. The Bryant 2002 trial reported a mean difference of 0.2
episodes per day (Analysis 4.2: mean difference (MD) -0.20, CI -
1.02 to 0.62), whereas theWells 2011 trial reported ’no difference’
with no numerical data provided.No informationwas available for
cure and improvement rates based on quantification of symptoms
or generic quality of life.
5) Reduction in sweetened fizzy or diet drinks versus
no treatment
We found no trials that compared a reduction in sweetened fizzy
or diet drinks with no treatment.
6) Reduction in alcohol consumption versus no
treatment
We found no trials that compared a reduction in alcohol con-
sumption with no treatment.
7) Avoiding constipation versus no treatment
We found no trials that compared avoidance of constipation with
no treatment.
8) Smoking cessation versus no treatment
We found no trials that compared stopping smoking with no treat-
ment.
9) Restricting strenuous physical forces versus no
treatment
We found no trials that compared restricting strenuous physical
forces with no treatment.
10) Reducing high levels of, or increasing low levels of,
physical activity versus no treatment
We found no trials that compared a reduction in high levels of
physical activity, or increasing low levels of physical activity, with
no treatment.
11) Any lifestyle interventions, either alone or in
combination, versus other lifestyle interventions or
pharmacological and other conservative therapies
One trial was identified that compared a lifestyle weight loss in-
tervention versus metformin. This trial was a sub-study of a large
DPP trial for diabetes described above (Brown 2006b), which
compared different weight loss programmes: an intensive lifestyle
intervention or a pharmacological intervention (metformin). This
comparison included 1296 women.
The only relevant outcome for this review was the effect of weight
loss on the prevalence of weekly or more frequent UI at a mean
follow-up of 2.8 years. The results showed that women allocated to
the lifestyle group (N=659) had a significantly lower prevalence of
UI (any UI) compared with those in the comparison group (252/
659 (38%) versus 306/635 (48%), RR 0.79, 95%CI 0.70 to 0.90;
Analysis 5.1.1). The results hold for the prevalence of both weekly
SUI symptoms (206/659 (31%) versus 252/635 (40%), RR 0.79,
95% CI 0.68 to 0.91; Analysis 5.1.2), and UUI symptoms (156/
659 (24%) versus 182/635 (29%), RR 0.83, 95%CI 0.69 to 0.99;
Analysis 5.1.3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Soy-rich diet compared to control for the treatment of urinary incontinence in adults
Patient or population: adults with urinary incontinence
Settings:
Intervention: soy-rich diet
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Soy rich diet
Cure rates by patient ob-
servation (all UI types) -
not reported
Not estimable -
Improvement rates by
patient observation (all
UI types) - not reported
Not estimable -
Condition-specific qual-
ity of life - not reported
Not estimable -
Adverse effects - not re-
ported
Not estimable -
Cure rates by symp-
tom quantification (all UI
types) - not reported
Not estimable -
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Improvement rates by
symptom quantification
(all UI types) - not re-
ported
Not estimable -
Incontinent episodes per
week (all UI types) - not
reported
Not estimable -
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; UI: urinary incontinence
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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Decreasing fluids compared to increasing fluids for the treatment of urinary incontinence in adults
Patient or population: adults with urinary incontinence
Settings:
Intervention: decreasing fluids
Comparison: increasing fluids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Increasing fluids Decreasing fluids
Cure rates by patient ob-
servation (all UI types) -
not reported
Not estimable -
Improvement rates by
patient observation (all
UI types) - not reported
Not estimable -
Condition-specific qual-
ity of life
Follow-up: 1 weeks
See comment See comment Not estimable 69
(1 study1)
⊕©©©
very low2,3,4,5,6
Quality of life improved
when fluid intake was de-
creased but the impact of
incontinence on daily life
did not differ significantly
before or after the treatment
Adverse effects
Follow-up: 1 weeks
See comment See comment Not estimable 93
(2 studies1)
⊕©©©
very low2,3,5,6,7,8
Reported adverse effects
include constipation, thirst,
headache and concen-
trated urine with decreas-
ing fluids
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Cure rates by symp-
tom quantification (all UI
types) - not reported
Not estimable -
Improvement rates by
symptom quantification
(all UI types) - not re-
ported
Not estimable -
Incontinent episodes per
week (all UI types)
Follow-up: 1-4 weeks
See comment See comment Not estimable 125
(3 studies9)
⊕©©©
very low2,3,5,6,8,10,11
Decreasing fluid intake sig-
nificantly reduced inconti-
nent episodes in one study,
no difference was found in
another study and the re-
sults were inconclusive in
the other study
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; UI: urinary incontinence
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Randomised cross-over trial
2 Risk of bias: We downgraded the evidence by one level because blinding of participants, personnel and outcome assessors was
probably not done and could introduce bias.
3 Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation
concealment method.
4 Missing outcome data in 18% of participants.
5 Indirectness: We downgraded the evidence by two levels because of short follow-up <12 months in all studies and because study
participants included both continent and incontinent patients in one study (Hashim 2008)
6 Imprecision: We downgraded the evidence by one level because confidence intervals for relative effect were not estimable.
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7 Missing outcome data in 18% of participants in one study (Swithinbank 2005), whereas the other study had no missing outcome data
(Hashim 2008).
8 Inconsistency: We downgraded the evidence by one level because becuse of heterogenous interventions.
9 One RCT compared increasing versus decreasing versus maintaining fluid intake (Dowd 1996) and two randomized cross-over trials
comparing increasing versus decreasing fluid intake (Hashim 2008; Swithinbank 2005).
10 Missing outcome data in 45% of participants in the RCT (Dowd 1996), 18% of participants in a cross-over trial (Swithinbank 2005),
whereas the other cross-over trial had no missing outcome data (Hashim 2008).
11 Low adherence to the protocol was reported in two studies (Dowd 1996;Hashim 2008).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Caffeine reduction compared to control for the treatment of urinary incontinence in adults
Patient or population: adults with urinary incontinence
Settings:
Intervention: caffeine reduction
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Caffeine reduction
Cure rates by patient ob-
servation (all UI types) -
not reported
Not estimable -
Improvement rates by
patient observation (all
UI types) - not reported
Not estimable -
Condition-specific qual-
ity of life
ICIQ Overactive Bladder
Symptoms Quality of Life.
Scale from: 25 to 160.
Better quality of life indi-
cated by lower values.
Follow-up: 2 weeks
The mean condition-spe-
cific quality of life in the
control groups was
68.36 points
The mean condition-spe-
cific quality of life in the
intervention groups was
14.45 lower
(95% CI not estimable)
Not estimable 11
(1 study1)
⊕©©©
very low2,3,4,5,6
Adverse effects - not re-
ported
Not estimable -
Cure rates by symp-
tom quantification (all UI
types) - not reported
Not estimable -
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Improvement rates by
symptom quantification
(all UI types) - not re-
ported
Not estimable -
Incontinent episodes per
day (all UI types)
Follow-up: 4 weeks
The mean number of in-
continent episodes per
day (all UI types) in the
control groups was
1.4
The mean number of in-
continent episodes per
day (all UI types) in the
intervention groups was
0.2 lower
(1.02 lower to 0.62
higher)
Not estimable 74
(1 study7)
⊕©©©
very low2,4,5,6,8
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Randomised cross-over trial; feasibility study.
2 Risk of bias: We downgraded the evidence by one level because blinding of participants, personnel and outcome assessors was
probably not done.
3 Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation
concealment method.
4 Missing outcome data in >20% of participants.
5 Indirectness: We downgraded the evidence by two levels because of short follow-up <12 months and because study participants
included both continent and incontinent patients.
6 Imprecision: We downgraded the evidence by one level because confidence intervals for relative effect were not estimable.
7 A quasi-randomised controlled trial based on health record numbers.
8 Risk of bias: We downgraded the evidence by one level because allocation concealment was inadequate (quasi-randomisation based
on health record numbers).
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Lifestyle weight loss compared to metformin weight loss for the treatment of urinary incontinence in adults
Patient or population: adults with urinary incontinence
Settings:
Intervention: lifestyle weight loss
Comparison: metformin weight loss
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Metformin weight loss Lifestyle weight loss
Cure rates by patient ob-
servation (all UI types) -
not reported
Not estimable -
Improvement rates by
patient observation (all
UI types) - not reported
Not estimable -
Condition-specific qual-
ity of life - not reported
Not estimable -
Adverse effects - not re-
ported
Not estimable -
Cure rates by symp-
tom quantification (all UI
types) - not reported
Not estimable -
Improvement rates by
symptom quantification
(all UI types) - not re-
ported
Not estimable -
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Prevalence of weekly UI
(all UI types)
Follow-up: mean 2.8
years
482 per 1000 381 per 1000
(337 to 434)
RR 0.79
(0.7 to 0.9)
1294
(1 study)
⊕©©©
very low1,2,3,4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias: We downgraded the evidence by one level because blinding of participants, personnel and outcome assessors was not
mentioned and may introduce bias.
2 Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation
concealment method.
3 Missing outcome data in 11% of participants.
4 Indirectness: We downgraded the evidence by one level because data come from a sub-study of a trial (Brown 2006) for diabetes that
included continent as well as incontinent patients.
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D I S C U S S I O N
This is the first systematic review to consider the effectiveness of
specific lifestyle interventions in the management of adults with
urinary incontinence.
Summary of main results
This review identified eleven trials that reported on the effect of
weight loss (four trials), the intake of a soy-rich diet (one trial),
change in fluid intake (three trials), reduction in caffeinated drinks
(three trials), and lifestyle versus non-lifestyle interventions for
weight loss (one trial). No trials were identified that investigated
alcohol, sweetened fizzy drinks or diet drinks, constipation and
straining, smoking cessation, physical activity or physical forces.
Adverse effects appeared to be relatively uncommon for all in-
terventions studied, although, with decreasing fluids, some par-
ticipants experienced thirst, constipation, concentrated urine or
headaches.
Is weight loss by obese or overweight adults more
effective than no treatment?
Four trials investigated whether weight loss by obese or overweight
adults was more effective than no treatment and included a total
of 4701 women (Brown 2006b; Phelan 2012; Subak 2005; Subak
2009). It is important to note that two trials, which contributed
over 90% of the women to this analysis, were primarily diabetes
trials (N = 1321 and 2994, respectively; Brown 2006b; Phelan
2012).
There is ’low’ quality evidence that, compared with the control in-
terventions, weight loss programmes were associated with higher
improvement rates based on women’s self-report (primary out-
come), and also higher cure and improvement rates based on quan-
tifiable symptoms (secondary outcomes), although there was no
information available on self-reported cure (primary outcome).
The two diabetes trials also reported prevalence of urinary inconti-
nence and identified a similar trend towards the weight loss groups
having a greater reduction in the number ofwomenwithweekly in-
continence episodes compared with the control groups (’very low’
quality evidence).Only the smallest trial with 40womenmeasured
disease-specific quality of life using the Incontinence ImpactQues-
tionnaire and the Urogenital Distress Inventory (Subak 2005),
which showed statistically significant differences that favoured the
weight loss group compared with the control group (’low’ quality
evidence).
This consistency of effect across a number of measured outcomes
gives strength to the evidence. Overall, the differences in both cure
and improvement when weight loss is compared to control sug-
gest that weight loss interventions may be of interest to morbidly
and moderately obese women and their clinicians. The degree of
improvement in UI may be contingent upon the magnitude of the
weight loss. A cohort analysis, Wing 2010, associated with one of
the included trials (called the PRIDE study, N = 338 at baseline;
Subak 2009) showed that women who lost 5% to 10% of their
bodyweight (regardless of randomized treatment assignment)were
two to four timesmore likely to achieve at least a 70% reduction in
the number of total (i.e. stress or urgency) incontinence episodes
per week compared with those who gained weight at follow-ups at
six months (adjusted OR 3.7, 95% CI 1.6 to 8.2), at 12 months
(adjusted OR 3.7, 95% CI 1.7 to 8.3) and at 18 months (adjusted
OR 2.4, 95% CI 1.1 to 5.1). Weight losses greater than 10% did
not result in greater improvements in incontinence outcomes (at
6 months, adjusted OR 3.8, 95% CI 1.5 to 9.6; at 12 months,
adjusted OR 4.1, 95% CI 2.1 to 7.9; at 18 months, adjusted OR
3.3, 95% CI 1.7 to 6.4).
There is little evidence available concerning the potential mecha-
nisms involved in the weight loss effect. There was inconsistency
in the type of intervention provided that included various combi-
nations of diet and physical activity. It was also unclear whether
the dietary mechanism involved reduced calorie intake, or other
change in the quality of the diet, or both. Some of the potential
benefits of weight loss could also have been attributed to better
glycaemic control rather than weight loss alone, in view of the
substantial numbers of diabetics involved in the trials. Such results
may not be entirely relevant to all people with obesity, although
there was independent evidence for a weight loss effect in non-
diabetics.
As might be expected, the benefit of the weight loss intervention
diminished over time. This is clear from the forest plots for cure
and improvement rates by quantification of symptoms and the
number of incontinence episodes per week, which show that the
point estimates move closer to the line of no effect from three
months, through to18months.Maintenance of effect is rarely seen
in long-term incontinence trials carried out years after intervention
(Agur 2008;Glazener 2005), and therefore sustainability of weight
loss and its long-term effect on incontinence would require further
research.
Is dietary change more effective than no change?
One small trial investigated whether dietary change is more ef-
fective than no change (Manonai 2006); it included 42 women
comparing a soy-rich diet with a soy-free diet. The only available
outcome data for UI frequency found no evidence of a difference
between the two diets (’very low’ quality evidence). Other data
were insufficient to draw any conclusions about the effect of the
content of the diet on UI.
Is changing the volume of fluid intake more effective
than no change in the volume of fluid intake?
Three trials investigated whether changing the volume of fluid
intake is more effective than no change in the volume of fluid
intake; these included 181 women and 11 men (Dowd 1996;
Hashim 2008; Swithinbank 2005). Only one cross-over trial used
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disease-specific quality of life as the primary outcome and re-
ported improvement in scores for the Bristol Female Lower Uri-
nary Tract Symptoms questionnaire following decreased fluid in-
take (Swithinbank 2005). One trial reported poor adherence to
the intervention protocol, which led to inconclusive results (Dowd
1996). Each trial used a different protocol detailing fluid manip-
ulation and none of the trials reported improvement or cure. We
ranked the quality of findings as ’very low’.
Is caffeine reduction more effective than no change in
caffeine consumption?
Three trials investigated whether caffeine reduction is more ef-
fective than no change in caffeine consumption and included a
total of160 women and nine men (Bryant 2002; Miller 2007;
Wells 2011).One trial was reported exclusively via an author email
(Miller 2007), and was insufficiently detailed for us to draw firm
conclusions. Across the trials, there was inconsistency in outcomes
used, limited data and insufficient reporting to enable an analysis
of whether caffeine reduction is better than no change in con-
sumption. The limited and ’very low’ quality data available on
disease-specific quality of life (ICIQ-OABqol) and incontinence
episode frequency found no evidence of a difference between the
groups.
Is any lifestyle intervention more effective than
another intervention?
One trial investigated whether one lifestyle intervention is more
effective than any another intervention and included 1296 women
(Brown 2006b); this was a sub-study of a large diabetes trial that
compared two weight loss programmes - an intensive lifestyle in-
tervention or a pharmacological intervention (metformin). The
only available outcome data were on the effect of weight loss on
prevalence of weekly UI (a secondary outcome of ’very low’ evi-
dence quality). The results showed that women had a lower preva-
lence of weekly UI in the lifestyle group than in the metformin
group at a mean of 2.8 years follow-up and this difference between
the groups was statistically significant, favouring the lifestyle in-
tervention.
Overall completeness and applicability of
evidence
The majority of included trials had small sample sizes, with 60 or
fewer participants, and short follow-up (i.e. less than 12 months).
Five of the included trials were parallel-arm RCTs (Brown 2006b;
Dowd1996; Subak 2005; Subak 2009; Phelan2012). The remain-
der included four randomized cross-over trials (Hashim 2008;
Manonai 2006; Swithinbank 2005; Wells 2011), and one quasi-
RCT(allocationmade usinghealth recordnumbers; Bryant 2002).
We also included one unpublished trial, with limited information,
from an author email (Miller 2007).
Participants in the trials included in this review were predomi-
nantly female, with the average age (unclear if this was mean or
median) ranging from 49 to 58 years, except for two trials with
means of 62.7 years, Hashim 2008, and 70.25 years, Dowd 1996.
The trial participants were also those resident in the commu-
nity. Therefore, the applicability of findings to men and older age
groups, and particularly frail elderly people in care home settings,
is uncertain.
Random sequence allocation was adequately generated and con-
cealed in only two trials (Subak 2005; Subak 2009); in other trials
it was either inadequate or not described in sufficient detail. This
may have introduced selection bias.
The percentage of participants followed up and included in anal-
ysis varied across the included trials. Only four trials had either
no missing outcome data, imputed missing data, or stated that
missing data were balanced across groups (Brown 2006b; Hashim
2008; Subak 2005; Subak 2009), while in one trial nearly half of
the participants were excluded from analysis due to missing data
(Dowd 1996). In the other trials, the numbers of and reasons for
missing outcome data were not clearly described, which led to un-
certainty about the degree of attrition bias present in these trials.
Reported outcome data were heterogenous in a number of ways
and this limited our ability to make comparisons across trials. For
example, within each category of lifestyle intervention (weight
loss, diet quality, fluid restriction and caffeine restriction), the
trials used no outcomes consistently. There was no single outcome
common to all trials, and even outcomes that were conceptually
similar weremeasured in different ways. No primary outcome data
were available for six of the trials included in the review (Brown
2006b; Bryant 2002; Dowd 1996; Manonai 2006; Miller 2007;
Phelan 2012). In particular, quality-of-life outcomes were very
poorly recorded. The importance of the inclusion of quality-of-life
outcomes should not be underestimated, as they are likely to be the
most keenly valued by patients themselves. More recent trials are
likely to include quality-of-life measures, as they are increasingly
identified as key outcomes, and use of recognised instruments
for measuring them, such as the International Consultation on
Incontinence Questionnaire (ICIQ), are becoming more widely
used.
Quality of the evidence
We assessed the levels of evidence for each outcome measured
at 12 months after the commencement of the treatment us-
ing the GRADE approach (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3;
Summary of findings 4; and Summary of findings 5). Overall,
the GRADE level of evidence for all outcomes was either ’low’ or
’very low’ across the different interventions. The main factors for
downgrading the evidence included risk of bias (lack of blinding
and unclear allocation concealment), indirect evidence (less than
12 months of follow-up) and imprecise results due to a small sam-
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ple size with wide confidence intervals, or a lack of information
(e.g. standard deviation) required to estimate confidence intervals.
Evidence from studies where only some of the participants were
incontinent was also downgraded for indirectness as described be-
low.
Quality of outcome reporting was generally poor. We judged
methodological quality (risk of bias) from the trial reports, and so
our judgements may reflect the quality of reporting, rather than
the actual methodological quality of the trials.
Potential biases in the review process
Due to the limited number of trials we identified that included
only adults with UI, we made a post hoc decision to include data
from trials where not all participants were incontinent when they
entered the trial: the populations in these trials primarily had:
overactive bladder (Hashim 2008; Miller 2007; Wells 2011); ur-
gency and frequency (Bryant 2002); urogenital atrophy (Manonai
2006), or diabetes (Brown 2006b; Phelan 2012). Baseline incon-
tinence ranged from 27% of the trial participants in Phelan 2012
to 83% in Bryant 2002, or was not reported but assumed (Brown
2006b). We extracted outcome data from the whole study for all
trials except Phelan 2012, which provided subgrouped data spe-
cific to incontinence status.
We made another post hoc decision to include an outcome on the
prevalence of UI at follow-up; this outcome was identified from
the two weight loss trials in people with diabetes (Brown 2006b;
Phelan 2012). Our literature search was systematic and designed
to pick up any mention of UI, urinary leakage or overactive blad-
der in the title, abstract and controlled vocabulary. A more in-
depth search required to identify studies for all clinical conditions
was, however, not feasible within the limited resources available.
This may have introduced reporting bias, as a large or beneficial
intervention effect on UI may be more likely to be reported in
abstracts of published reports than data showing little or no effect,
and so be more likely to be identified by our search. If this is the
case, including prevalence data could have exaggerated interven-
tion effects. The applicability of evidence for managing people
with urinary incontinence may also be limited, as the extent to
which the weight loss programmes served as prevention, rather
than treatment, of urinary incontinence is unclear.
Although every effort was made to adhere to the review proto-
col to minimise bias, these post hoc decisions resulted in changes
to the inclusion criteria of the review. As data from those studies
with mixed populations (with and without incontinence) often
constituted the only information available for some of the inter-
ventions assessed in the review, we chose to include these data to
provide relevant, albeit indirect, evidence. We exercised caution
when interpreting these findings, by downgrading the quality of
the body of evidence for the outcomes based on the studies with
mixed populations (with and without incontinence) by one level
on the ground of indirectness.
The review also encountered a problem associated with cross-over
trials that did not report data in a standard way which would take
into account the within-person differences (paired analysis). In-
stead, the included trials tended to report all measurements after
completion of the treatment period and compared these data, as
if they were a parallel group; some included trials also reported all
measurements before and after intervention and compared these
data within each treatment phase. The information required to
perform paired analyses was not available from the published re-
ports, which meant not only that the data from similar trials could
not be incorporated into ameta-analysis, but also that the reported
data presented a ’unit of analysis’ error. These results should there-
fore be interpreted with caution.
The addition of the assessment of evidence quality using the
GRADE approach and ’Summary of findings’ tables was a rela-
tively new development in the systematic review methods at the
time of this review. While these methods were not specified in the
protocol, we nevertheless attempted to incorporate them into the
present review. Efforts were made tominimise bias in determining
outcomes to be included in the tables and quality ratings for each
outcome through careful discussion among the review authors.
However, these steps may have been influenced by knowledge of
the results of the research and may therefore carry some risk of
bias.
Agreements and disagreements with other
studies or reviews
We are unaware of other systematic reviews on this topic.However,
a summary of the evidence in men and in women, including that
from non-randomised studies, is provided in the 5th Edition of
the International Consultation on Incontinence (Moore 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available data show that evidence for weight loss as a treat-
ment to reduce urinary incontinence (UI) among morbidly and
moderately obese women is building, and might be worth con-
sidering as an initial treatment prior to other standard treatments
such as pelvic floor muscle training and surgery. However, there
is insufficient evidence to inform practice reliably about the effec-
tiveness of lifestyle interventions in general.
Implications for research
The evidence for lifestyle changes for UI is strongest for the effects
of weight loss programmes, which should receive research priority.
Weight loss interventions involving diet and fluid manipulation
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require more well designed trials that using representative sam-
ples of cases. Priority should also be given to investigating dietary
mechanisms for weight loss effects, such as calorie reduction, spe-
cific food or drink items and nutrient content as well as the role of
physical activity. Where specific evidence of effectiveness exists, as
in weight loss, lifestyle interventions should be further evaluated
as first-line treatments.
The review identified a complete lack of randomized trials for
lifestyle factors that are generally supposed to increase inconti-
nence, such as the intake of alcohol, sweetened fizzy or diet drinks,
smoking, physical forces, or clinical constipation and straining.
The widespread use of such lifestyle advice to moderate these fac-
tors in the hope of reducing UI, and the observational evidence
we identified, suggest a need for further research in these areas.
There is a need for separate consideration of the components of
multi-faceted lifestyle interventions in trials. Combining a number
of individual interventions, whose efficacy has not been evaluated
independently, in trials makes it impossible to determine which
factors affect change. Ideally, the initial research focus should be on
those areas where evidence is building (e.g. weight loss) or where
healthcare advice often promotes lifestyle interventions in the ab-
sence of evidence (e.g. caffeine consumption). The results of such
trials could then feed into a multi-faceted lifestyle intervention
trial that would reflect common practice and be rooted in a sound
evidence base.
It is expected that more recent trials are likely to have fewer
methodological problems. Ongoing improvements in the quality
of reporting, and incorporation of consistent use of CONSORT
(Consolidated Standards of ReportingTrials, http://www.consort-
statement.org/), should impact on the inclusion of trials in subse-
quent systematic reviews, ensuring that the most robust evidence
contributes to clinical recommendations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 2006b
Methods Design: A sub-study of the Diabetes Prevention Program (DPP), an RCT with over-
weight non-diabetic individuals, randomly allocated to the intensive lifestyle weight loss
programme (Group I), metformin (Group II) or placebo (Group III). For the purpose
of this sub-study, men were excluded from analysis
Study centre: 27 centres in the USA
Recruitment period: 1996-1999
Power calculation: performed for the original DPP trial
Participants Number of (female) participants randomized: total = 2191
Number of (female) participants followed up: total = 1957; Group I = 660; Group II =
636; Group III = 661
Withdrawals/dropouts/lost to follow-up: total = 234 (11%) women with missing UI
data were excluded from analysis
Gender: female
Mean age, years (SD): Group I: 49.3 (10.6); Group II: 49.9 (9.6); Group III: 49.5 (9.7)
BMI mean (SD): Group I: 34.7 (6.9); Group II: 34.8 (6.9); Group III: 35.1 (7.0)
Ethnicity:
Group I: white = 343; African American = 138; Hispanic = 103; Native American = 51;
Asian = 25
Group II: white = 333; African American = 148; Hispanic = 97; Native American = 45;
Asian = 13
Group III: white = 355; African American = 144; Hispanic = 94; Native American = 51;
Asian = 17
Education: not stated
Employment status: not stated
Severity of symptoms: not stated
Prior incontinence surgery: not stated
Inclusion criteria: age at least 25 years, BMI ≥ 24 kg/m², a fasting plasma glucose level
95-125 mg/dl, and a 2-h post challenge glucose level 140-199 mg/dl
Exclusion criteria: people taking medications that could affect glucose tolerance or who
had serious medical illness
Diagnostic groups: not stated
Interventions Group I: intensive lifestyle intervention. The goals were at least 7% weight loss and at
least 150 minutes of moderate-intensity physical activity per week. A 16-lesson curricu-
lum covering diet, exercise, and behaviour modification, taught by case managers during
the first 24 weeks after enrolment, was “flexible, culturally sensitive, and individualized”.
Subsequent individual sessions (usually monthly) and group sessions with the case man-
agers were also provided to reinforce the behavioural changes
Treatment duration: 24 weeks with monthly follow-up thereafter
Length of follow-up: average 2.8 (range 1.8-4.6) years
Training provided by: case managers, with training in nutrition, exercise or behaviour
modification, on a one-to-one basis
Group II: metformin 850 mg twice daily with standard lifestyle intervention
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Brown 2006b (Continued)
Group III: placebo twice daily with standard lifestyle intervention
The standard lifestyle intervention included written information and an individual meet-
ing (20-30 minutes) that emphasized a healthy diet, reduced weight, increased activity
levels and smoking cessation, at baseline and annually
Co-interventions: not stated
Compliance: Mean change in weight, kg (SD): Group I = -3.4 (8.2); Group II = -1.5 (7.
6); Group III = +0.5 (6.7); P value < 0.001
Outcomes Weekly prevalence of UI by type (stress, urge or any UI) based on participant’s report at
the end-of-trial visit
Notes The primary aim of the DPP trial was to evaluate whether an intensive lifestyle inter-
vention with improved diet and increased physical activity or metformin therapy among
overweight pre-diabetic men and women would prevent or delay the onset of type 2
diabetes. Not all participants had UI at baseline. The objective of the analysis included
in this review was to assess whether these interventions were associated with a lower
prevalence of incontinence in women, because weight loss may decrease incontinence,
whereas increased physical activity may worsen incontinence, and incontinence may also
be a barrier to exercise
Funding: The DPP trial was supported by the following: The Diabetes Prevention Pro-
gram, National Institutes of Health/National Institute of Diabetes and Digestive and
Kidney Diseases, the National Institute of Child Health and Human Development, the
National Institute on Aging, the Office of Research onMinority Health and Health Dis-
parities, theOffice ofWomen’sHealth, the IndianHealth Service, theCenters forDisease
Control and Prevention, the General Clinical Research Program, theNational Center for
Research Resources, the American Diabetes Association, Bristol-Myers Squibb, Lipha
Pharmaceuticals, and Parke-Davis. LifeScan, Health O Meter, Hoechst Marion Rous-
sel, Merck-Medco Managed Care, Merck, Nike Sports Marketing, and Slim Fast Foods.
Quaker Oats donated materials, equipment, or medicines for concomitant conditions.
McKesson ioServices, Matthews Media Group, and the Henry M Jackson Foundation
provided support services under subcontract with the Co-ordinating Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Adaptive randomisation stratified
by clinical centre”
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Assignments to metformin and placebo
were blinded but the lifestyle intervention
was not
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
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Brown 2006b (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 2191 women enrolled in the 3 arms
of the DPP, 234 (11%) women with miss-
ing UI data were excluded from the analy-
sis. The study stated that “women missing
data on urinary incontinence did not differ
in incident diabetes, mean weight change,
or mean change in physical activity over-
all or within treatment groups compared
with women with completed urinary in-
continence data”
Selective reporting (reporting bias) Unclear risk Insufficient information provided. The
main outcome for this analysis was preva-
lence of incontinence
Other bias Unclear risk The DPP trial was closed early after 2.9
years when lifestyle changes andmetformin
treatment had each reduced the incidence
of diabetes
Bryant 2002
Methods Design: quasi-RCT. Participants were randomized by health record numbers and allo-
cated to caffeine reduction education (Group I) or control (Group II)
Study centre: 2 nurse-led continence clinics, Sydney, Australia
Recruitment period: not stated
Power calculation: performed
Funding: not stated
Participants Number of participants randomized: total = 95; Group I = 48; Group II = 47
Number of participants followed up: total = 74; Group I = 36; Group II = 38
Withdrawals/dropouts/lost to follow-up: total = 21 (22%); Group I = 12; Group II =
9. Reasons: failure to return to follow-up (n = 14); anxiety or family problem (n = 4);
hospital admission (n = 2); intercurrent illness (n =1)
Gender (number and % female): Group I = 45 (94%); Group II = 41 (87%)
Mean age, years (SD): Group I = 56 (18); Group II = 58 (16)
Mean body weight, kg (SD): Group I = 69 (17); Group II = 68 (20)
Ethnicity: not stated
Education: not stated
Employment status: not stated
Severity of symptoms: mean number of leakage episodes per 24 hours (SD): Group I =
2.8 (3.2); Group II = 3.1 (3.9)
Prior incontinence surgery: not stated
Inclusion criteria: adults with symptoms of urgency, frequency and/or urge incontinence,
and who routinely ingested caffeine at levels of 100 mg or more every 24 hours
Exclusion criteria: significant cognitive impairment, pregnancy or symptoms of urinary
tract infection
Diagnostic groups: 83%of the sample had urgeUI, while 17% reported noUI at baseline
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Bryant 2002 (Continued)
(only frequency and urgency)
Interventions Group I: educational intervention (with bladder training) to reduce caffeine intake to
< 100 mg a day. The intervention consisted of a thorough review (with participants) of
their caffeine intake history, urinary symptoms and time/volume/caffeine charts for 3
randomly selected 24-hour periods, followed by a planned caffeine reduction interven-
tion using a caffeine fading method (James 1988). This method decreases caffeine intake
by one drink each day until the desired maximum intake of 100 mg caffeine a day is
reached and the caffeinated drinks have been replaced by other fluids
Treatment duration: participants were seen weekly for 4 weeks
Length of follow-up: no follow-up after 4-week programme
Training provided by: not stated
Group II: continued usual daily caffeine intake of > 100 mg every 24 hours. Also received
bladder training
Co-interventions: not stated
Compliance: mean caffeine intake reduction per 24 hours, (SD):
Group I: 58%; Group II: 11%; P value < 0.0001
Outcomes Number of incontinent episodes in 24 hours
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were randomized by
health record number to two groups”
Allocation concealment (selection bias) High risk Quote: “Patients were randomized by
health record number to two groups”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported for 74 (78%) of 95 partic-
ipants who completed the study. Reasons
for withdrawal were reported but not sepa-
rately for each group. The study states that
caffeine levels did not differ between the
completers and those who withdrew, but
it is unclear if severity of incontinence dif-
fered
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Bryant 2002 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information. Reported out-
comes specified in the method section
Other bias Unclear risk Insufficient information provided
Dowd 1996
Methods Design: RCT. Participants were assigned randomly to increased fluid intake (Group I),
decreased fluid intake (Group II) or maintained fluid intake (Group III)
Study centre: USA
Recruitment period: not stated
Power calculation: not stated
Participants Number of participants randomized: total = 58; Group I = 20; Group II = 18; Group
III = 20
Number of participants followed up: total = 32; Group I = 14; Group II = 10; Group
III = 8
Withdrawals/dropouts/lost to follow-up: total = 26 (45%); Group I = 6; Group II = 8;
Group III = 12. Reason: diaries were not sufficiently completed
Gender: female
Mean age, years (range): 70.25 (52-89)
BMI: 19/32 participants with data had normal or belownormal weight; 8/32 participants
were obese
Ethnicity: not stated
Education: not stated
Employment status: not stated
Severity of symptoms (mean daily UI episodes per day): 0.6 (n = 32)
Prior incontinence surgery: not stated
Inclusion criteria: women over 50 years of age who had had UI for 6 months or more,
were independent in self-care, scored over 20 on the Mini-Mental State Examination
(Folstein 1975) and were English speaking
Exclusion criteria: not stated
Diagnostic groups: not stated
Interventions The first week served as the baseline, after which participants were assigned to 1 of the
3 groups. Participants were instructed in the detailed recording of intake using the same
measuring cups and glasses for the duration of the study and were instructed to keep
intake and output diaries for 5 weeks
Group I: increased fluid intake by 500 ml, total intake not to exceed 2400 ml per day
Group II: decreased intake by 300 ml, total intake not to be less than 1000 ml per day
Group III: maintained fluid intake at baseline level
Treatment duration: 5 weeks (randomisation in second week)
Length of follow-up: a 3-month telephone follow-up (n = 29) was undertaken for the
entire cohort; no data were available for each randomized group
Treatment provided by: registered nurses who were given in-service training on UI and
oriented to the study procedures. They provided new data-collection sheets and re-
sponded to questions on a weekly basis
Co-interventions: not stated
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Dowd 1996 (Continued)
Compliance (mean daily fluid intake): Group I = fluid intake was increased until week 3
when they returned closer to the baseline level; Group II = intake was less than baseline
through the first 4 weeks but increased in week 5; Group III = increased intake by
approximately 170 ml in week 5; this suggests generally low compliance across the groups
Outcomes Number of incontinent episodes in 24 hours
Notes The secondary aim of the study was to assess whether there was any relationship between
caffeine intake and incontinence episodes
Funding: Kidney Foundation of Summit County in Akron, Ohio, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The women were assigned ran-
domly”
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were presented for 32/58 (55%) of
the women randomized who maintained
the diaries for the entire study
Selective reporting (reporting bias) Unclear risk Insufficient information provided. The
only outcome reported was the number of
incontinence episodes, but this was accord-
ing to the study aim
Other bias High risk The study reported that adherence to the
fluid manipulation was poor and made re-
sults difficult to interpret
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Hashim 2008
Methods Design: prospective 2-group cross-over trial. After a 4-day screening period (baseline),
there were 4 phases of 4-day fluid manipulation and 2-day washout over the period of
4 weeks. Participants were randomly assigned to 1 of the 2 groups and asked either to
increase or decrease their fluid intake first, from baseline
Study centre: Bristol Urological Institute, Southmead Hospital, Bristol, UK
Recruitment period: not stated
Power calculation: performed
Participants Number of participants randomized: 67 were contacted, 40 were recruited and 24 were
randomized
Number of participants followed up: 24
Withdrawals/dropouts/lost to follow-up: none
Gender: male = 11; female = 13
Age (years): mean 62.7, median (range) 62.5 (42, 80)
BMI: not stated
Ethnicity: not stated
Education: not stated
Employment status: not stated
Severity of symptoms: not stated
Prior incontinence surgery: not stated
Inclusion criteria: adult men and women (≥18 years old) with symptoms of OAB.
Enrolled after a 4-day screening period (to establish baseline values) using frequency/
volume charts (FVC), completed daily, if they had a mean of 8 or more voids and 1
or more urgency and/or urgency incontinence episodes in 24 hours. Participants were
identified from a database that included those who were contacted and/or participated
in previous trials. They were initially screened by telephone to see if they would agree to
take part in the trial and were eligible for it
Exclusion criteria: participants were excluded from any part of the study if their increase/
decrease resulted in them drinking > 3 L or < 1 L of fluid, as drinking 3 L would be
excessive and drinking < 1 L would cause symptoms of dehydration, e.g. headaches and
constipation. People were also excluded if they were pregnant or breast-feeding; had
haematuria, bacteriuria, pyuria, proteinuria, glucosuria or ketosuria on urine dipstick
testing; had a residual volume of > 150 mL, as assessed by a bladder scan; had uncon-
trolled hypertension, suspicion or evidence of clinically relevant cardiac failure, renal
disease or hepatic disease; were diagnosed with or suspected of having diabetes insipidus/
primary polydipsia or diabetes mellitus; had neurogenic dysfunction of the lower urinary
tract; were known alcohol or drug abusers; were scheduled to be admitted to hospital
for inpatient surgery during the trial; had any history of clinically relevant psychiatric
disorders within the last 24 months preceding enrolment in the trial; had a history of not
complying with medical regimens or were not compliant with protocol requirements or
unable to keep a diary or perform the required volume measurements on their own; had
significant pelvic organ prolapse (Stage III or IV) or had significant stress UI
Diagnostic groups: OAB = 24 (100%). Only 7 (29%) participants had 1 or more urge
UI episode at baseline
Interventions 4-day screening period with FVC to establish baseline drinking habits, prior to randomi-
sation to Group I or II
Group I:
4 days drinking 25% less than baseline followed by 2 days normal drinking (i.e. a
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washout); followed by
4 days drinking 50% less than baseline followed by 2 days normal drinking; followed by
4 days drinking 25% more than baseline followed by 2 days normal drinking; followed
by
4 days drinking 50% more than baseline
Group II:
4 days drinking 25% more than baseline followed by 2 days normal drinking; followed
by
4 days drinking 50% more than baseline followed by 2 days normal drinking; followed
by
4 days drinking 25% less than baseline followed by 2 days normal drinking; followed by
4 days drinking 50% less than baseline
Participants who drank > 3 L or < 1 L were excluded. Patients completed a 4-day FVC
in each part of the study, and the ICIQ-OAB questionnaire at the end of each 4-day
period, to assess their quality of life for that period
Significance was analyzed by comparing each intervention group to the overall baseline
of the study group (n = 24). The number of participants differed in each period so this
is presented for reference
Treatment duration: 4 weeks
Co-intervention: not stated
Compliance: all 24 participants participated in the period with a 25% reduction, but
not all participated in the other parts of the study because they did not fulfil the criteria,
i.e. their input was < 1 L or > 3 L when the fluid intake was manipulated. The mean fluid
output was approximately 289 ml higher than the fluid intake. When participants were
asked to drink 25%more than their normal fluid input they only managed to drink 17%
more, and when asked to drink 50% more they managed 23% more, when comparing
the respective groups with baseline.When asked to drink 50% less, participants managed
to drink 32% less than the baseline. The 25% reduction was adhered to quite well
Outcomes Condition-specific quality of life
Adverse effects
Number of incontinent episodes in 24 hours
Notes Funding: Bristol Urological Institute PA Research Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized into one of the two
groups”
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but unlikely
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcomes
Selective reporting (reporting bias) Unclear risk Insufficient information available. The
study described what was measured by fre-
quency/volume charts in the method sec-
tion
Other bias High risk The study reported that participants had
difficulty in adhering to the study protocol
when they were asked either to increase or
decrease fluids by 50%
Manonai 2006
Methods Design: cross-over trial with 2 x 12-week diet periods and 2 x 4-week washout periods
before and between treatments. Participants were randomly allocated to the order in
which they followed an isocaloric soy-rich diet or a control diet
Study centre: Mahidol University, Bangkok, Thailand
Recruitment period: not stated
Power calculation: not stated
Participants Number of participants randomized: 42
Number of participants followed up: 36
Withdrawals/dropouts/lost to follow-up = 6. Reasons: 5withdrew from the study because
of their inability to comply with the study; 1 lost to pelvic examination follow-up
Gender: female
Mean age, years: 52.5 (SD 5.11; range 40-59)
BMI: not stated
Ethnicity: not stated
Education: not stated
Employment status: not stated
Severity of symptoms: not stated
Prior incontinence surgery: not stated
Inclusion criteria: healthy women whose periods had ceased at least 3 months previously,
who were 45-70 years of age, not using hormone therapy and did not regularly consume
a vegetarian diet. All women had experienced at least one type of urinary or genital
symptoms owing to urogenital atrophy
Exclusion criteria: presence or history of sex hormone-dependent malignancies; presence
or history of liver or renal disorders; and pathology of urogenital tract
Diagnostic groups: before soy-rich diet, 61% had SUI and 19% had UUI; and before
control diet 63% had SUI and 11% had UUI. Some women may have had symptoms of
both SUI and UUI. Other women had frequency, urgency or other vaginal symptoms,
e.g. vaginal dryness, but no UI
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Interventions During both study periods, participants consumed self-selected diets with low-fat and
low-cholesterol foods. Subjects were advised to maintain their physical activity consis-
tently throughout the study and were instructed to avoid all additional soy products,
herbal or vitamin and mineral supplements. They were also instructed to keep an accu-
rate 3-day food record
Intervention period I: isocaloriic soy-rich diet: Participants consumed 25 g soy protein
in various forms containing > 50 mg per day of isoflavones, which was substituted for an
equivalent amount of animal protein. All soy foods for the study were provided monthly
Intervention period II: control diet
Treatment duration: 2 x 12-week diet periods with 2 x 4-week washout periods before
and between treatments
Treatment provided by: the same nutritionist throughout the study
Co-intervention: not stated
Compliance: good compliance was shown by the significant elevation of serum levels of
daidzein and genistein during the soy-rich diet period
Outcomes Number of women with incontinent episodes
Incontinence symptom scores
Notes Funding: Thai Health Promotion Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The subjects were randomized
into two groups”
Allocation concealment (selection bias) Unclear risk No information available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Pelvic examination and vaginal pH test
were performed by the same examiner who
was blinded, but these outcomes were not
relevant to this review. No mention of
blinded assessment for the outcomes spec-
ified in the review
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data are presented for 36 (86%) of 42
women who completed the study. Reasons
for withdrawals and drop-outs were de-
scribed but their incontinence severity was
unclear and it was also unclear at what time
point the withdrawals/drop-out occurred
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Selective reporting (reporting bias) Unclear risk Insufficient information available. Re-
ported outcomes were specified in the
methods section
Other bias Unclear risk Insufficient information available
Miller 2007
Methods Design: RCT with 2 groups
Study centre: University of Michigan School of Nursing, USA
Study period: 01 January 2007-31 December 2007
Participants Number of participants: Group I = around 30; Group II = around 30
Gender: female
Diagnostic groups: OAB (unclear if wet or dry)
Interventions Group I: reduced intake of ’irritating’ beverages (caffeine or non-caffeine). Participants
were instructed to maintain the overall volume of fluid intake by replacing the ’irritating’
beverages with water or milk
Group II: control (no details provided)
Treatment duration: unclear
Outcomes The study found a significant reduction inOAB symptoms (not defined) in the interven-
tion group. However, the author noted that findings were confounded by a significant
reduction in overall fluid intake in the intervention group from baseline (by an average of
8 fluid oz (around 230 ml) per 24 hours). The author also notes that caffeine reduction
was not associated with the OAB symptom reduction
Notes Unpublished trial. All information was obtained from an author email to the Cochrane
Incontinence Group search co-ordinator (26 January 2009)
Funding: Pfizer, GA6120A8 Detrol Competitive Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information available
Allocation concealment (selection bias) Unclear risk Insufficient information available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information available
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information available
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias High risk The study author noted non-adherence to
the protocol among study participants
Phelan 2012
Methods Design: a sub-study of the Look AHEAD (Action for Health in Diabetes) trial, an
RCT with overweight or obese individuals with type 2 diabetes, randomly allocated to
intensive lifestyle weight loss intervention (Group I) or a diabetes support and education
control condition (Group II). For the purpose of this sub-study, men were excluded from
analysis
Study centre: 16 centres, USA
Recruitment period: from 2001. Planned follow-up until 2014
Power calculation: performed
Participants Number of (female) participants randomized in Look AHEAD trial: 3063. Of these, 69
who did not complete baseline incontinence assessment were excluded from this sub-
study
Number of randomized participants in this sub-study: Group I = 1495; Group II = 1499
Number of participants followed up: Group I = 1385; Group II = 1354
Withdrawals/dropouts/lost to follow-up: Group I = 110; Group II = 145. Study com-
pleters were more likely to be white (P value = 0.01) and to be never smokers (P value =
0.02) than non-completers, but no other significant differences were observed
Gender: female
Mean age, years (SD): Group I: 57.8 (6.7); Group II: 58.1 (6.9)
Mean BMI (SD): Group I: 36.3 (6.2); Group II: 36.7 (6.0)
Ethnicity:
Group I: non-Hispanic white 56%, African-American 20%, Hispanic 15%, Native
American/Alaskan native 6%, Other 3%;
Group II: non-Hispanic white 55%, African-American 20%, Hispanic 15%, Native
American/Alaskan native 7%, Other 3%
Education: not stated
Employment status: not stated
Severity of symptoms: not stated
Prior incontinence surgery: not stated
Inclusion criteria: overweight and obese individuals (men and women) with type 2
diabetes, 45-76 years of age with a BMI of ≥ 25 kg/m² (> 27 kg/m² if currently taking
insulin)
Exclusion criteria: ≥ HbA1c 11%, blood pressure ≥ 160/100 mmHg, triglycerides ≥
600 mg/dl, inadequate control of comorbid conditions, factors that may limit adherence
to the intervention, and underlying disease likely to limit life span and/or affect safety
of the interventions
Diagnositic groups: at baseline 27% of participants reported weekly (or more frequent)
urinary incontinence. The reference group was ’less than weekly’. Predominant type
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of UI was coded based on whether a participant reported a higher frequency of stress
or urgency episodes. About 13% in each group reported predominant SUI and 10%
reported predominant UUI. Only 2% of women were classified as having MUI (defined
as frequency of SUI = frequency of UUI)
Interventions Group I: intensive lifestyle intervention designed to promote an average of 7% or greater
weight loss at 1 year. Participants were encouraged to consume a low calorie and low fat,
portion controlled diet that included liquid meal replacements, and to achieve at least
175 minutes of physical activity weekly. The participants were seen weekly for the first
6 months and 3 times monthly for the next 6 months for a total of 44 sessions (Phase I,
months 1-12)
Treatment duration: the intensive intervention occurred in the first 4 years of the study
period (e.g. Phase II, months 13-48; Phase III, months 49+)
Length of follow-up: for the purpose of this sub-study, outcomes were assessed after 1
year of intervention
Training provided by: lifestyle counsellor
Group II: diabetes support and education: participants were invited to 3 group sessions
during the year which focused on diet, physical activity or social support
Co-interventions: not reported
Compliance: Mean weight lost at 1 year, kg (SD): Group I: 7.7 (7.0); Group II: 0.7 (5.
0); P value < 0.0001
Outcomes Improvement (decrease of at least 2 episodes per week) and resolution (cure) in women
who hadweekly or more frequent incontinence episodes at baseline, assessed by validated
self-report questions after 1 year of intervention
Prevalence of UI (that occurred at least weekly) assessed by validated self-report questions
after 1 year of intervention
Notes The primary objective of the LOOK AHEAD trial was to assess the intervention effects
on cardiovascular morbidity and mortality
Funding: the Department of Health and Human Services. The following organizations
have committed to make major contributions to Look AHEAD: FedEx Corp; Health
Management Resources; LifeScan, Inc, a Johnson and Johnson Company; Optifast ®
of Nestle HealthCare Nutrition, Inc; Hoffmann-La Roche Inc; Abbott Nutrition; and
Slim-Fast Brand of Unilever North America
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Partiicpants were randomly as-
signed within centers to the ILI [inten-
sive lifestyle intervention] or the DSE [di-
abetes support and education] conditions
with equal probability”. “Randomisation
is stratified by clinical center and blocked
with random block sizes”
Allocation concealment (selection bias) Unclear risk No information available
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of patient and personnel notmen-
tioned but unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All measures were completed at
baseline and 1 year by assessors who were
masked to participant treatment group.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of the 3063 women enrolled in the Look
AHEAD trial, 69 (2%) women with no
UI data at baseline were excluded from
this sub-study. The 1-year follow-up rate
was 93% (1385/1495) in the intervention
group and 90% (1354/1499) for the con-
trol group. Survey completers were more
likely to be white and non-smokers. The
implication for the incontinence outcome
is unknown
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Unclear risk Insufficient information available
Subak 2005
Methods Design: RCT stratified by type of incontinence (either stress only and stress-predominate
MUI or urge only and urge-predominate MUI), then randomly allocated to immediate
(Group I) or delayed (Group II) enrolment in the weight reduction programme
Study centre: University of California, USA
Recruitment period: January 1999-March 2000
Power calculation: performed
Participants Number of participants randomized: total = 48; Group I = 24; Group II = 24
Number of participants followed up: total = 40; Group I = 19; Group II = 21
Withdrawals/dropouts/lost to follow-up: total = 8; Group I = 5 (2 loss to follow-up for
unknown reasons, 1 medical exclusion, 2 missing primary outcome data); Group II = 3
(2 lost to follow-up for unknown reasons, 1 withdrew from study due to death of spouse)
Gender: female
Median age, years (IQR): Group I = 50.5 (46-54); Group II = 57.5 (50-62); P value =
0.006
Median BMI (IQR): Group I = 34 (32-40); Group II = 36 (32-38)
Ethnicity:
Group I: white = 18; other 2; Group II: white = 17; other = 3
Education: not stated
Employment status: not stated
Severity of symptoms (number of women with ’severe’ incontinence defined as > 10
episodes per week): Group I = 19; Group II = 20
Prior incontinence surgery (number of women): Group I = 1; Group II = 3
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Inclusion criteria: a consecutive sample of women 18 to 80 years old with BMI between
25-45 kg/m², UI for at least 3 months and at least 4 incontinent episodes in a 7-day
urinary diary. Prior incontinence therapies (including surgery) were not exclusions from
study eligibility
Exclusion criteria: pregnancy, urinary tract infection, significant medical condition,
pelvic cancer, neurological condition possibly associated with incontinence, interstitial
cystitis or potential inability to complete the study
Diagnostic groups:
Group I: stress alone = 3; stress-predominate MUI = 9; urge alone = 3; urge-predominate
MUI = 9 Group II: stress alone = 0; stress-predominate MUI = 10; urge alone = 2; urge-
predominate MUI = 11
Interventions Group I: a 3-month intensive group-based medical and behavioural weight loss pro-
gramme. Participants were placed on a standard low calorie liquid diet (800 kcals per
day or less), encouraged to increase physical activity gradually until they were exercising
60 minutes daily, and were taught standard cognitive and behavioural skills to assist
in modifying eating and exercise habits. Participants met weekly in group sessions led
by a nutritionist, exercise physiologist or behavioral therapist and followed a structured
protocol
Treatment duration: 3 months
Length of follow-up: 3 and 6 months after completion of the 3-month programme for
the entire cohort; no data were available for each randomized group
Training provided by: nutritionist, exercise physiologist or behavioural therapist
Group II: a waiting list control group had no intervention for 3months and then entered
the weight reduction programme
Co-interventions: participants currently using incontinence therapy were included in
the study, but were asked to not change treatment during study
Compliance: median % weight improvement, (IQR): Group I: 16 (9-20); Group II: 0
(-2-2)
Outcomes Condition-specific quality of life
Adverse effects
Cure rates based on quantification of symptoms (defined as number of women with a
100% reduction in weekly UI episodes recorded by 7-day diary)
Improvement (including cure) rates based on quantification of symptoms (defined as
number of women with a 75%-100% reduction in weekly UI episodes recorded by 7-
day diary)
Number of incontinent episodes per week
Generic quality of life
Notes Funding: Mount Zion Health Services Inc and University of California
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization codes were
prepared by computer generated random
numbers”
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Allocation concealment (selection bias) Low risk Quote: “sealed, opaque envelopes num-
bered consecutively”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Participants could not be blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “... research investigators assess-
ing outcomes and statistical analysts were
blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The analysis was “by intent to treat”. The
study states that the “40women (83%)who
completed the first 3 months of the trial
were similar in demographic and clinical
characteristics to the 8 women (17%) who
did not complete the first 3 months of the
trial”
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Unclear risk Imbalance in age at baseline due to chance
(P value = 0.006), the effect(s) on outcome
are unknown
Subak 2009
Methods Design: RCT stratified by clinical centre, then randomly allocated by 2:1 ratio to 6-
month weight loss programme (Group I) or 4-session education programme (Group II)
Study centre: multiple centres in Alabama, USA (PRIDE study)
Recruitment period: 2004-2006
Power calculation: performed
Participants Number of participants randomized: total = 338; Group I = 226; Group II = 112
Number of participants with data on incontinence at 6 months: total = 304; Group I =
214; Group II = 90
Withdrawals/dropouts/lost by 6months: total = 34;Group I = 12 (5 discontinued; 3were
unwilling to follow the program, 1 had a medical reason and 1 had schedule conflicts;
7 did not fill diary); Group II = 22 (15 discontinued; 10 were unwilling to follow the
programme, 3 had family problems, 1 was disappointed by the group assignment and 1
had schedule conflicts; 7 did not fill diary)
Number of participants with data on incontinence at 12 months: total = 294; Group I
= 207; Group II = 87
Number of participants with data on incontinence at 18 months: total = 287; Group I
= 197; Group II = 90
Gender: female
Mean age, years (SD): Group I = 53 (11); Group II = 53 (10)
Mean BMI (SD): Group I = 36 (6); Group II = 36 (5)
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Ethnicity:
Group I: white = 171; black = 47; other = 8; Group II: white = 91; black = 17; other = 4
Education (beyond high school): Group I = 200; Group II = 93
Employment status: not stated
Severity of symptoms: not stated
Prior incontinence surgery: none (see exclusion criteria)
Inclusion criteria: women at least 30 years of age, BMI of 25-50, and at baseline reported
10 or more UI episodes in a 7-day diary of voiding. Previous medical therapy for incon-
tinence or obesity did not affect eligibility
Exclusion criteria: use of medical therapy for incontinence or weight loss within the
previous month, current urinary tract infection or ≥ 4 or more urinary tract infections
in the previous year, a history of incontinence of neurologic or functional origin (due
to factors not involving the lower urinary tract, such as chronic impairment of physical
or cognitive functioning), previous surgery for incontinence or urethral surgery, major
medical or genitourinary tract conditions, pregnancy or parturition in the previous 6
months, type 1 or type 2 diabetes mellitus requiring medical therapy that increased the
risk of hypoglycemia, and uncontrolled hypertension
Diagnostic groups:
Group I: stress alone = 8; stress-predominant (at least 2/3 of the total number of episodes
were stress episodes) = 36; urge alone = 33; urge-predominant (at least 2/3 of the total
number of episodes were urge episodes) = 71 MUI with no predominant type = 78;
Group II: stress alone = 10; stress-predominant = 21; urge alone = 8; urge-predominant
= 37; MUI with no predominant type = 36
Interventions At randomisation, all participants were given a self-help behavioural-treatment booklet
with instructions for improving bladder control (including pelvic floor muscle training)
. Incontinence was not discussed further with either group
Group I: weight loss programme designed to produce an average loss of 7% to 9% of
initial body weight within the first 6 months of the program, modelled after that used
in 2 large clinical trials: the Look AHEAD (Action for Health in Diabetes), and the
DPP (Diabetes Prevention Program). Participants met weekly for 6 months in groups of
10-15 for 1-hour sessions that were led by experts in nutrition, exercise, and behaviour
change and were based on a structured protocol. Given a standard reduced-calorie diet
(1200-1500 kcal per day), with a goal of providing no more than 30% of the calories
from fat. To improve adherence, the participants were provided with sample meal plans
and were given vouchers for a meal-replacement product (Slim-Fast) to be used for 2
meals a day during months 1-4 and for 1 meal a day thereafter. Encouraged to increase
physical activity (brisk walking or activities of similar intensity) gradually until active for
at least 200 minutes each week. Behavioural skills, including self-monitoring, stimulus
control, and problem-solving, were emphasized
Treatment duration: 6 months
Follow-up (weight loss maintenance): On completion of the 6-month programme, par-
ticipants underwent a second randomisation to a motivationally focused maintenance
programme or a standard skills based maintenance approach and were followed for fur-
ther 12 months
Training provided by: experts in nutrition, exercise, and behaviour change
Group II: structured education programme (control): 4 education sessions at months
1, 2, 3, and 4. During these 1-hour group sessions, which included 10-15 women,
general information was presented about weight loss, physical activity, and healthful
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eating habits, according to a structured protocol
Co-intervention: see exclusion criteria
Compliance (mean weight, kg (SD)):
Group I: baseline = 98 (17); 6 months = 90 (17); Group II: baseline = 95 (16); 6 months
= 94 (17)
Compliance (weight % change(95% CI)):
Group I: 6 months = -8.0 (-9.0 to - -7.0); 12 months = -7.5 (-8.6 to - -6.4); 18 months
= -5.5 (-6.7 to - -4.3); Group II: 6 months = -1.6 (-2.7 to - -0.4); 12 months = -1.7 (-3.
2 to - -0.2); 18 months = -1.6 (-3.4 to - 0.7)
Outcomes Improvement rates based on participant’s report (women reported that overall leakage
was better or much better)
Cure rates based on quantification of symptoms (defined as number of women reporting
a 100% reduction in weekly UI episodes recorded by 7-day voiding diary)
Improvement rates based on quantification of symptoms (defined as number of women
with a 70%-100% reduction in weekly UI episodes recorded by 7-day voiding diary)
Change in the number of incontinent episodes per week
Notes Funding:the National Institute of Diabetes and Digestive and Kidney Diseases and the
Office of Research on Women’s Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed
with the use of randomly permuted blocks
of three or six, stratified according to clin-
ical center”
Allocation concealment (selection bias) Low risk Quote: “... random assignment [was] con-
cealed in tamper-proof envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The participants were aware of
their treatment assignment ...”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “... the staffmembers who collected
the outcome data were not” aware of their
treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Baseline variables, including age,
race, parity, BMI, type of incontinence,
frequency of incontinence episodes, and
pad weight were not significantly associ-
ated with the retention of participants at 6
months”. Also, multiple imputation meth-
ods were used for missing data
The study stated that “Participants who
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dropped out of the study had a higher
number of baseline UI episodes than com-
pleters ... but dropouts in the intervention
and control groups did not differ” (Wing
2010b)
Selective reporting (reporting bias) Unclear risk Insufficient information available. Re-
ported outcomes were specified in the
methods section
Other bias Unclear risk Insufficient information available
Swithinbank 2005
Methods Design: cross-over trial with random allocation to the order in which participants in-
creased or decreased decaffeinated fluids in weeks 3 or 4
Study centre: Bristol Urological Institute, Southmead Hospital, Bristol, UK
Recruitment period: not stated
Power calculation: performed
Participants Number of participants randomized: 110 women were approached to enter the study,
26 refused, the remaining 84 were included in the study (by incontinence type: USI =
48; IDO = 36)
Number of participants followed up: total = 69; USI group = 39; IDO group 30
Withdrawals/dropouts/lost to follow-up: total = 15; USI group = 9 (19%); IDO group
= 6 (17%). No reasons provided
Gender: female
Median age, years (range): 54.8 (31-76)
BMI: not stated
Ethnicity: not stated
Education: not stated
Employment status: not stated
Severity of symptoms: not stated
Prior incontinence surgery: not stated
Inclusion criteria: women with USI or IDO: women in the IDO group had been re-
ferred for investigation of symptoms of frequency, urgency and urgency incontinence,
and women with USI had been referred because of leakage secondary to coughing and
exercise; the USI group was naive to surgery
Exclusion criteria: urinary tract infection, hepatic, cardiac or renal disease, diabetes mel-
litus; those on anti-depressants, anticholinergics or diuretics
Diagnostic groups: USI = 48; IDO = 36
Interventions Treatment duration: 4 weeks
Week 1: participants drank normally (baseline)
Week 2: all participants drank normally, but only caffeine-free fluids
Weeks 3 and 4: participants were randomized to either increasing caffeine-free fluids
to 3 L (20 cups) per day for a week followed by a week of reducing caffeine-free fluids
to 750 ml (5 cups) per day, or vice versa. Results from the weeks with increased and
decreased fluids were compared. Urine osmolality was measured at weekly clinic visit to
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assess compliance
Detailed urinary diaries that included information concerning episodes of urgency and
leakage were kept for each day of the 4-week study period. A reason for randomising
the order of increased or decreased fluid intake was to counter the placebo effect (e.g. a
bladder training effect) of keeping urinary diaries
Co-interventions: not stated
Compliance (mean fluid intake per day, ml; all women with USI or IDO): week 1 =
1639 ml; week 2 with caffeine-free fluids = 1630 ml; week increasing fluid = 2673 ml;
week decreasing fluid: 872 ml
Outcomes Condition-specific quality of life
Adverse effects
Number of incontinent episodes in 24 hours
Notes Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized in the order in which
[participants] increased and decreased flu-
ids”
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data not available for 15 (18%) of 84 par-
ticipants enrolled. Reasons for this were not
provided
Selective reporting (reporting bias) Unclear risk Insufficient information available. Re-
ported outcomes were specified in the
methods section
Other bias Unclear risk Insufficient information available
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Wells 2011
Methods Design: cross-over trial with random allocation to the order in which participants con-
sumed caffeinated or caffeine-free fluids (feasibility study)
Study centre: single centre, UK
Recruitment period: not reported
Power calculation: not reported
Participants Number of participants randomized: total = 14
Number of participants followed up: 11
Withdrawals/dropouts/lost to follow-up: 3 withdrawals
Gender: female
Mean age, years (range): 52.1 (27-79)
BMI: not reported
Ethnicity: not reported
Education: not reported
Employment status: not reported
Severity of symptoms: not reported
Prior incontinence surgery: not reported
Inclusion criteria: women aged > 18 years with newly diagnosed OAB, experiencing > 7
voids per day and > 2 episodes per night, self-rated urgency and/or UUI with or without
stress incontinent symptoms, and consuming > 2 caffeinated drinks per day (minimum
60 mg caffeine per 24 hours)
Exclusion criteria: stress incontinence only, smoking, taking oestrogen and/or medica-
tions containing caffeine or interfere with caffeine metabolism, postvoid residual < 100
ml, history of frequent (> 3/6 months) [sic] urinary tract infections, pregnant, or unable
to undertake a bladder diary
Diagnositic groups: OAB with or without UI
Interventions All participants underwent 2 x 2-week periods of caffeinated and caffeine-free fluid intake
with the 2 periods separated by a 14-day washout period. Before starting their assigned
period, participants took part in a run-In period of caffeine withdrawal, during which
they were requested to reduce their caffeine intake by substituting one cup of caffeinated
tea or coffee with decaffeinated every other day
Co-interventions: not reported
Compliance: “2 participants did not comply with caffeine substitution” based on caffeine
levels from saliva samples
Outcomes ICIQ-OAB; ICIQ-OABqol
Number of incontinent episodes (3-day bladder diary)
Notes Available as abstract only
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “… randomized … via random
number generator”
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Wells 2011 (Continued)
Allocation concealment (selection bias) Unclear risk No information available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned but unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14 randomized and 11 completed the fol-
low-up (79%). No further details
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias High risk 2 participants did not comply with caffeine
substitution
Abbreviations
BMI: body mass index
DPP: Diabetes Prevention Program
FVC: frequency volume charts
HbA1c: glycated haemoglobin
ICIQ-OAB: Internatioanal Consultation on Incontinence Questionnaire Overactive Bladder
ICIA-OABqol:Internatioanal Consultation on Incontinence Questionnaire Overactive Bladder Symptoms Quality of Life
IDO: idiopathic detrusor overactivity
MUI: mixed urinary incontinence
OAB: overactive bladder
oz: (fluid) ounce
RCT: randomized controlled trial
SD: standard deviation
SUI: stress urinary incontinence
UI: urinary incontinence
USI: urodynamic stress incontinence
UUI: urgency urinary incontinence
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
BE-DRI Anticholinergic medications plus behavioural training versus anticholinergic medications alone. Behavioural
training included specific fluid management as well as pelvic floor muscle control and exercises, urge suppression,
and delayed voiding. Study conducted by the Urinary Incontinence Treatment Network (UITN). Complex
interventions for which we could not separate the effect of lifestyle interventions
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(Continued)
Bird 2005 Not a relevant population. Healthy volunteers (N = 80). Caffeine tablet versus placebo. Outcome: perceived
change in LUTS
Brown 2007 Self-management plus standard care versus standard care. Self-management included lifestyle (fluid, caffeine,
alcohol), bladder training and toileting. Complex intervention meant we could not separate the effect of lifestyle
interventions
Dougherty 2002 BMC versus control. BMC = lifestyle change, if needed; if lifestyle not needed, bladder training (BT); if BT not
effective, PFMT + biofeedback (BF). Complex intervention meant we could not separate the effect of lifestyle
interventions
Dumoulin 2011 Physiotherapy versus control. Physiotherapy treatment combined 1) PFMT and other exercises with 2) dietary
recommendations/changes and constipation management. We could not separate the effect of (2) from (1)
Glazener 2001 Not a relevant intervention. PFMT (for all UI) plus bladder training (for urge UI) versus control
Herschorn 2003 Tolterodine plus health education intervention versus tolterodine alone. N = 84. Abstract only, so no details of
health education intervention available. Possibly related to Herschorn 2004
Herschorn 2004 Health education intervention plus tolterodine versus tolterodine alone. Participants received a behavioural
modification information sheet with multiple components including: 1) fluid intake regulation, 2) caffeine
limitation, 3) scheduled toileting, 4) bladder stretching, 5) PFMT, and 6) urge suppression. We could not
separate the effect of 1) and 2) from the rest
Hofbauer 1990 Not a relevant intervention. Electrical stimulation (ES) + ’gymnastic’ versus ’gymnastic’ versus ES versus sham
ES. German publication
Kim 2011a Multidimensional exercise treatment, consisting of stretching, PFMT and fitness exercises. Community-dwelling
elderly Japanese women with SUI, UUI or MUI. We could not separate the effect of non-PFMT exercise
Kim 2011b Exercise treatment with or without heat and steam generating sheet (HSGS). Exercise consisted of stretching,
PFMT and fitness exercises. A 4-arm trial comparing: 1) exercise +HSGS, 2) exercise only, 3) HSGS only, and 4)
education. Community-dwelling elderly Japanese women with stress, urge or mixed UI. We could not separate
the effect of non-PFMT exercise
Kincade 2007a Described the characteristics of women participating in 2 clinical trials and explored the relationships between
demographic characteristics, caffeine and fluid intake, quality of life, and severity of urine loss. No usable data
Kincade 2007b Self-monitoring including: 1) caffeine, 2) fluid intake, 3) PFMT, 4) voiding frequency, 5) constipation. We
could not separate the effect of lifestyle change
Li 2001 The study did not focus on UI, but assessed the effects of Tai Chi on physical function. The only incontinence-
related outcome was use of toilet, as part of a composite measure of “eating, dressing, bathing or using the toilet”
Parker 2005 Not a relevant population. Healthy volunteers (N = 64). Caffeine tablet versus placebo. Outcome: LUTS.
Abstract only. Probably related to Bird 2005
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(Continued)
Ree 2007 The study did not focus on UI, but examined whether strenuous physical activity could produce pelvic floor
muscle fatigue among young nulliparous women with stress UI. No outcome data on UI
Schauss 2006 Not a relevant intervention. ’UroLogic’ versus placebo. UroLogic is a nutritional supplement containing Equi-
setum arvense and Crataeva murvale
Tomlinson 1999 Complex intervention for which we could not separate the effect of lifestyle change. BMC versus control. The
three phases of BMC were: 1) self-monitoring including fluid management and caffeine reduction; 2) bladder
training; and 3) pelvic muscle exercise with biofeedback. 218 women were randomized into treatment or control.
Analysis focused on 41 women who were randomized into the treatment and completed the first phase of BMC.
No data were available for the control group
Van Hespen 2006 Not a relevant population. RCT of the UI training programme, INCOndition, including training of pelvic floor
muscles, bladder function and mobility, for women living in homes for the elderly.German with English abstract
Wagg 2007 Lifestyle leaflet versus structured help in clinic (including BT and PFMT). Leaflet-only interventions, without
a standardised (within trial) protocol, are not eligible
Abbreviations
BF: biofeedback
BMC: behavioural management for continence
BT: bladder training
ES: electrical stimulation
LUTS: lower urinary tract symptoms
MUI: mixed urinary incontinence
PFMT: pelvic floor muscle training
RCT: randomized controlled trial
SUI: stress urinary incontinence
UI: urinary incontinence
UUI: urgency urinary incontinence
Characteristics of studies awaiting assessment [ordered by study ID]
Baker 2011
Methods RCT
Participants Women with urgency incontinence
Interventions Mindfulness-based stress reduction technique and yoga (MBSR-yoga) versus sham yoga
Outcomes Change from baseline in mean number of urge incontinent episodes from pre treatment to post treatment
Notes Estimated enrolment: 30
Study start date: February 2011
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Baker 2011 (Continued)
Primary completion date: May 2012 (final data collection date for primary outcome measure)
Gozukara 2014
Methods RCT
Participants Overweight/obese women with UI recorded in a 3-day diary
Interventions Behavioural weight loss versus structured education programme
Outcomes Change in voiding diary from baseline to 6 months in voiding diary parameters; Pelvic Floor Distress Inventory and
POP-Q
Notes Enrolment: 158
Study start date: June 2008
Heesakkers 2009
Methods RCT
Participants Patients with OAB
Interventions Low versus normal versus high fluid intake
Outcomes Urine osmolality; PPIUS (Perception of Intensity of Urgency Scale) urge-score
Notes Enrollment: 0
Study start date: July 2009
Primary completion date: December 2010 (final data collection date for primary outcome measure)
Huang 2012
Methods RCT
Participants Women with UI or OAB
Interventions Yoga therapy versus control
Outcomes Change in the number of incontinence episodes over 7 days from pre treatment to post treatment
Notes Enrollment: 20
Study start date: August 2012
Study completion date: December 2012
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Markland 2013
Methods RCT
Participants Older women with UI
Interventions Vitamin D supplementation versus placebo
Outcomes Change in the number of incontinent episodes on a 7-day bladder diary from the baseline evaluation to the final visit
at 12-weeks
Notes Estimated enrollment: 100
Study start date: January 2014
Estimated study completion date: November 2015
Seckin 2011
Methods RCT
Participants Individuals with incontinence due to stress or OAB
Interventions Aerobic pelvic floor muscle exercise versus targeted Pilates exercise group
Outcomes Change in SEAPI quality of life score from baseline
Notes Enrolment: 80
Poster only, minimal detail available
Wells 2014
Methods Randomised cross-over trial
Participants Women with newly diagnosed OAB and history of caffeine consumption
Interventions Group A: 14-day caffeinated drink period followed by a 14-day decaffeinated drink period
Group B: 14-day decaffeinated drink period followed by a 14-day caffeinated drink period (with a 14-day run-in
period and 14-day wash-out period between group entry
Outcomes Episodes of urgency and frequency, volume per void and incontinence recorded in a 3-day diary
Notes Enrolment: 11
Abbreviations
OAB: overactive bladder
POP-Q: Pelvic Organ Prolapse Quantification System
RCT: randomized controlled trial
SEAPI: stress-related leak (S), emptying ability (E), anatomy (A), protection (P), inhibition (I)
UI: urinary incontinence
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Characteristics of ongoing studies [ordered by study ID]
Moholdt 2011
Trial name or title Exercise Training in Pregnancy (ETIP) for obese women
Methods Design: randomised controlled trial with 2 parallel arms (intervention versus control)
Study centre: the Norwegian University of Science and Technology and the St Olav’s Hospital, Trondheim
University Hospital
Participants 150 previously sedentary, pregnant women with a pre-pregnancy BMI at or above 30 kg/m²
Interventions Intervention: organised exercise training 3 times per week
Control: standard antenatal care
Outcomes The main outcome measure will be weight gain from baseline to delivery
Secondary outcomes include incontinence
Starting date September 2010. Recruitment anticipated until the end of 2012
Contact information Trine TMoholdt, Department of Publich Health and General Practice, Norwegian University of Science and
Technology, Trondheim, Norway. Email: trine.moholdt@ntnu.no
Notes
Abbreviation
BMI: body mass index
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D A T A A N D A N A L Y S E S
Comparison 1. Weight loss versus no active intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement rates based on
women’s perception (all types
UI)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 At 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Improvement rates based on
women’s perception (all types
UI)
Other data No numeric data
3 Quality of life and symptom
scores
Other data No numeric data
4 Cure rates based on
quantification of symptoms (all
types UI)
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 At 3 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 At 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Cure rates based on
quantification of symptoms (by
type of UI)
Other data No numeric data
6 Improvement rates based on
quantification of symptoms (all
types UI)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 At 3 months 1 40 Risk Ratio (M-H, Fixed, 95% CI) 16.5 [1.01, 270.78]
6.2 At 6 months 1 304 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.22, 2.81]
6.3 At 12 months 2 1032 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.02, 1.44]
6.4 At 18 months 1 287 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.86, 1.55]
7 Improvement rates based on
quantification of symptoms (by
type of UI)
Other data No numeric data
8 Prevalence of weekly urinary
incontinence after intervention
(all types UI)
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 At 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 At 2.8 years 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Prevalence of weekly urinary
incontinence after intervention
(by type of UI)
Other data No numeric data
10 Incontinent episodes per week
(% change from baseline; all UI
types)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 At 18 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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11 Incontinence episodes per week
(% change from baseline; by
type of UI)
Other data No numeric data
Comparison 2. Soy-rich diet versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of women with UI
episodes: soy-rich diet versus
control
Other data No numeric data
2 Mean UI symptom scores (SD; 0
= none, 1 = mild, 2 = moderate,
3 = severe): soy-rich diet versus
control
Other data No numeric data
Comparison 3. Increase in fluid intake versus decrease in fluid intake
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Median number of daily UI
episodes (IQR)
Other data No numeric data
2 Median number of daily UI
episodes (range)
Other data No numeric data
3 Mean number of daily UI
episodes (any UI)
Other data No numeric data
Comparison 4. Caffeine reduction versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean quality of life scores Other data No numeric data
2 Mean number of UI episodes
per 24 hours (SD)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 5. Lifestyle weight loss versus metformin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prevalence of weekly UI after
intervention
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 All UI types at 2.8 years 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Stress UI at 2.8 years 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Urgency UI at 2.8 years 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Weight loss versus no active intervention, Outcome 1 Improvement rates
based on women’s perception (all types UI).
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 1 Weight loss versus no active intervention
Outcome: 1 Improvement rates based on women’s perception (all types UI)
Study or subgroup Weight loss Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 6 months
Subak 2009 163/214 49/90 1.40 [ 1.14, 1.71 ]
0.005 0.1 1 10 200
Favours control Favours weight loss
Analysis 1.2. Comparison 1 Weight loss versus no active intervention, Outcome 2 Improvement rates
based on women’s perception (all types UI).
Improvement rates based on women’s perception (all types UI)
Study Outcome Weight loss
(number
improved)
Weight loss
(t otal N)
Weight loss
(%)
Control
(number
improved)
Control
(t otal N)
Control
(%)
Reported P
value
Subak 2009 At 12
months (N=
298)
Not
reported
Not
reported
75 Not
reported
Not
reported
68 0.2
Subak 2009 At 18
months (N=
Not
reported
Not
reported
75 Not
reported
Not
reported
62 0.02
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Improvement rates based on women’s perception (all types UI) (Continued)
291)
Analysis 1.3. Comparison 1 Weight loss versus no active intervention, Outcome 3 Quality of life and
symptom scores.
Quality of life and symptom scores
Study Outcome Weight loss (to-
tal N)
Weight loss, me-
dian (IQR)
Control (total
N)
Control, median
(IQR)
Reported P
value
Subak 2005 3 months
Subak 2005 Incontinence Im-
pact Question-
naire (score range
0-400 with lower
score indicating
better quality of
life)
19 37 (11 to 86) 21 89 (56 to 136) 0.01
Subak 2005 Urogenital
Distress Inven-
tory (score range
0-300 with lower
scores indicating
less distress)
19 104 (67 to 122) 21 195 (156 to 228) <0.0001
Subak 2005 SF-36 physical
component
(higher scores in-
dicate better
quality of life)
19 55 (49 to 58) 21 47 (41 to 50) 0.003
Subak 2005 SF-36 mental
component
(higher scores in-
dicate better
quality of life)
19 48 (46 to 49) 21 51 (48 to 54) 0.09
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Analysis 1.4. Comparison 1 Weight loss versus no active intervention, Outcome 4 Cure rates based on
quantification of symptoms (all types UI).
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 1 Weight loss versus no active intervention
Outcome: 4 Cure rates based on quantification of symptoms (all types UI)
Study or subgroup Weight loss Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Subak 2005 3/19 0/21 7.70 [ 0.42, 140.03 ]
2 At 6 months
Subak 2009 15/214 4/90 1.58 [ 0.54, 4.62 ]
3 At 12 months
Phelan 2012 132/376 114/362 1.11 [ 0.91, 1.37 ]
0.01 0.1 1 10 100
Favours control Favours weight loss
Analysis 1.5. Comparison 1 Weight loss versus no active intervention, Outcome 5 Cure rates based on
quantification of symptoms (by type of UI).
Cure rates based on quantification of symptoms (by type of UI)
Study Outcome Weight loss
(number
cured)
Weight loss
(total N)
Weight loss
(%)
Control
(number
cured)
Control
(total N)
Control
(%)
Reported P
value
Subak 2009 Stress UI at
6 months
Not
reported
Not
reported
27 Not
reported
Not
reported
15 0.004
Subak 2009 Urgency UI
at 6 months
Not
reported
Not
reported
19 Not
reported
Not
reported
11 0.02
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Analysis 1.6. Comparison 1 Weight loss versus no active intervention, Outcome 6 Improvement rates
based on quantification of symptoms (all types UI).
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 1 Weight loss versus no active intervention
Outcome: 6 Improvement rates based on quantification of symptoms (all types UI)
Study or subgroup Weight loss Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 months
Subak 2005 7/19 0/21 100.0 % 16.50 [ 1.01, 270.78 ]
Subtotal (95% CI) 19 21 100.0 % 16.50 [ 1.01, 270.78 ]
Total events: 7 (Weight loss), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 At 6 months
Subak 2009 88/214 20/90 100.0 % 1.85 [ 1.22, 2.81 ]
Subtotal (95% CI) 214 90 100.0 % 1.85 [ 1.22, 2.81 ]
Total events: 88 (Weight loss), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0039)
3 At 12 months
Phelan 2012 139/376 119/362 76.1 % 1.12 [ 0.92, 1.37 ]
Subak 2009 95/207 27/87 23.9 % 1.48 [ 1.05, 2.09 ]
Subtotal (95% CI) 583 449 100.0 % 1.21 [ 1.02, 1.44 ]
Total events: 234 (Weight loss), 146 (Control)
Heterogeneity: Chi2 = 1.81, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 2.17 (P = 0.030)
4 At 18 months
Subak 2009 91/197 36/90 100.0 % 1.15 [ 0.86, 1.55 ]
Subtotal (95% CI) 197 90 100.0 % 1.15 [ 0.86, 1.55 ]
Total events: 91 (Weight loss), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
0.1 0.2 0.5 1 2 5 10
Favours control Favours weight loss
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Analysis 1.7. Comparison 1 Weight loss versus no active intervention, Outcome 7 Improvement rates
based on quantification of symptoms (by type of UI).
Improvement rates based on quantification of symptoms (by type of UI)
Study Outcome Weight loss
(number
cured)
Weight loss
(total)
Weight loss
(%)
Control
(number
cured)
Control
(total)
Control
(%)
Reported P
value
Subak 2009 Stress UI at
6 months
Not
reported
Not
reported
51 Not
reported
Not
reported
34 0.01
Subak 2009 Urgency UI
at 6 months
Not
reported
Not
reported
41 Not
reported
Not
reported
29 0.04
Subak 2009 Stress UI at
6 months
Not
reported
Not
reported
51 Not
reported
Not
reported
34 0.01
Subak 2009 Urgency UI
at 6 months
Not
reported
Not
reported
41 Not
reported
Not
reported
29 0.04
Subak 2009 Stress UI at
18 months
Not
reported
Not
reported
61 Not
reported
Not
reported
62 0.92
Subak 2009 Ur-
gency UI at
18 months
Not
reported
Not
reported
47 Not
reported
Not
reported
34 0.03
Analysis 1.8. Comparison 1 Weight loss versus no active intervention, Outcome 8 Prevalence of weekly
urinary incontinence after intervention (all types UI).
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 1 Weight loss versus no active intervention
Outcome: 8 Prevalence of weekly urinary incontinence after intervention (all types UI)
Study or subgroup Weight loss Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 12 months
Phelan 2012 350/1385 387/1354 0.88 [ 0.78, 1.00 ]
2 At 2.8 years
Brown 2006b 252/659 302/660 0.84 [ 0.74, 0.95 ]
0.5 0.7 1 1.5 2
Favours weight loss Favours control
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Analysis 1.9. Comparison 1 Weight loss versus no active intervention, Outcome 9 Prevalence of weekly
urinary incontinence after intervention (by type of UI).
Prevalence of weekly urinary incontinence after intervention (by type of UI)
Study Outcome Weight
loss (num-
ber
with UI)
Weight
loss (total
N)
Weight
loss (%)
Control
(number
with UI)
Control
(total N)
Control
(%)
Reported
P value
Reported
adjusted
odds ratio
(95% CI)
Brown
2006b
SUI at 2.8
years
206 659 31 242 660 37 0.04 0.80 (0.64
to 1.01)
Brown
2006b
UUI at 2.8
years
156 659 24 169 660 26 0.41 Not
reported
Phelan
2012
SUI at 1
year
145 1385 11 173 1354 13 0.07 0.73 (0.55
to 0.96)
Phelan
2012
UUI at 1
year
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
0.93 (0.70
to 1.23)
Analysis 1.10. Comparison 1 Weight loss versus no active intervention, Outcome 10 Incontinent episodes
per week (% change from baseline; all UI types).
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 1 Weight loss versus no active intervention
Outcome: 10 Incontinent episodes per week (% change from baseline; all UI types)
Study or subgroup Weight loss Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
Subak 2009 214 -47 (51.9496) 90 -28 (62.0685) -19.00 [ -33.59, -4.41 ]
2 At 12 months
Subak 2009 207 -57 (43.7854) 87 -45 (51.612) -12.00 [ -24.38, 0.38 ]
3 At 18 months
Subak 2009 197 -62 (35.5848) 90 -55 (47.745) -7.00 [ -18.04, 4.04 ]
-100 -50 0 50 100
Favours weight loss Favours control
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Analysis 1.11. Comparison 1 Weight loss versus no active intervention, Outcome 11 Incontinence episodes
per week (% change from baseline; by type of UI).
Incontinence episodes per week (% change from baseline; by type of UI)
Study Outcome Weight loss (to-
tal N)
Weight loss
(% change from
baseline)
Control (total
N)
Control
(% change from
baseline)
Reported P
value
Subak 2005 All UI
at 3 months, me-
dian (IQR)
19 -60 (-89 to -30) 21 -15 (-25 to 9) 0.0005
Subak 2005 Stress UI at 3
months, median
(IQR)
19 -92 (-100 to -66) 21 5 (-63 to 33) 0.003
Subak 2005 Urgency UI at 3
months, median
(IQR)
19 -70 (-100 to -16) 21 -11 (-67 to 69) 0.03
Subak 2005
Subak 2005
Subak 2005
Subak 2005
Subak 2005
Subak 2005
Subak 2009 All
UI at 6 months,
mean (95% CI)
214 -47 (-54 to -40) 90 -28 (-41 to -13) 0.01
Subak 2009 Stress
UI at 6 months,
mean (95% CI)
214 -58 (-67 to -46) 90 -33 (-50 to -9) 0.02
Subak 2009 Urgency UI at
6 months, mean
(95% CI)
214 -42 (-51 to -32) 90 -26 (-44 to -3) 0.14
Subak 2009 All
UI at 12 months,
mean (95% CI)
207 -57 (-63 to -50) 87 -45 (-56 to -32) 0.08
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Incontinence episodes per week (% change from baseline; by type of UI) (Continued)
Subak 2009 Stress
UI at 12 months,
mean (95% CI)
207 -66 (-71 to -59) 87 -45 (-59 to -27) <0.001
Subak 2009 Urgency UI at
12 months, mean
(95% CI)
207 -50 (-59 to -39) 87 -48 (-63 to -29) 0.87
Subak 2009 All
UI at 18 months,
mean (95% CI)
197 -62 (-67 to -55) 90 -55 (-65 to -43) 0.3
Subak 2009 Stress
UI at 18 months,
mean (95% CI)
197 -69 (-76 to -61) 90 -62 (-73 to -48) 0.32
Subak 2009 Urgency UI at
18 months, mean
(95% CI)
197 -56 (-64 to -46) 90 -49 (-64 to -28) 0.46
Analysis 2.1. Comparison 2 Soy-rich diet versus control, Outcome 1 Number of women with UI episodes:
soy-rich diet versus control.
Number of women with UI episodes: soy-rich diet versus control
Study Outcome Soy-rich diet (n/N) Soy-rich diet (%) Control diet (n/N) Control diet (%)
Manonai 2006 SUI episodes: before
(baseline)
22/36 61 23/36 63
Manonai 2006 SUI episodes: after 22/36 61 18/36 51
Manonai 2006 UUI episodes: before
(baseline)
7/36 19 4/36 11
Manonai 2006 UUI episodes: after 6/36 17 8/36 22
Analysis 2.2. Comparison 2 Soy-rich diet versus control, Outcome 2 Mean UI symptom scores (SD; 0 =
none, 1 = mild, 2 = moderate, 3 = severe): soy-rich diet versus control.
Mean UI symptom scores (SD; 0 = none, 1 = mild, 2 = moderate, 3 = severe): soy-rich diet versus control
Study Outcome Soy-rich diet (n = 36) Soy-rich diet (n = 36)
Manonai 2006 SUI episodes: before (baseline) 0.67 (0.68) 0.75 (0.65)
Manonai 2006 SUI episodes: after 0.72 (0.66) 0.72 (0.74)
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Mean UI symptom scores (SD; 0 = none, 1 = mild, 2 = moderate, 3 = severe): soy-rich diet versus control (Continued)
Manonai 2006 Reported P value > 0.05 > 0.05
Manonai 2006 UUI episodes: before (baseline) 0.17 (0.38) 0.14 (0.35)
Manonai 2006 UUI episodes: after 0.19 (0.47) 0.25 (0.50)
Manonai 2006 Reported P value > 0.05 < 0.05
Analysis 3.1. Comparison 3 Increase in fluid intake versus decrease in fluid intake, Outcome 1 Median
number of daily UI episodes (IQR).
Median number of daily UI episodes (IQR)
Study Type of UI Baseline Caffeine-free
baseline
Caffeine-free
and increasing fluids
Caffeine-free
and decreasing flu-
ids
Swithinbank 2005 Urodynamic stress
incontinence (SUI),
n = 39
1.6 (0.6 to 2.8) 0.8 (0.1 to 1.9) 0.7 (0.3 to 3) 0.5 (0.2 to 2.1)
Swithinbank 2005 Idiopathic detrusor
overactivity (IDO),
n = 30
0.9 (0.4 to 2) 0.6 (0.2 to 1.8) 1.1 (0.2 to 3) 0.5 (0.2 to 1.2)
Analysis 3.2. Comparison 3 Increase in fluid intake versus decrease in fluid intake, Outcome 2 Median
number of daily UI episodes (range).
Median number of daily UI episodes (range)
Study Randomised group N Median (range) Reported P value
compared with baseline
Hashim 2008 Baseline 24 0 (0, 4.8)
Hashim 2008 25% less fluid 24 0 (0, 5.5) 1.0
Hashim 2008 50% less fluid 12 0 (0, 4.5) 0.69
Hashim 2008 25% more fluid 21 0 (0, 10.3) 1.00
Hashim 2008 50% more fluid 14 0 (0, 12.8) 0.69
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Analysis 3.3. Comparison 3 Increase in fluid intake versus decrease in fluid intake, Outcome 3 Mean
number of daily UI episodes (any UI).
Mean number of daily UI episodes (any UI)
Study Time period Maintain fluid
(N = 14)
Increase fluid (N = 10) Decrease fluid (N = 8)
Dowd 1996 Week 1 (baseline) 0.48 0.6 0.54
Dowd 1996 Week 2 0.71 0.61 0.26
Dowd 1996 Week 3 0.81 0.67 0.17
Dowd 1996 Week 4 0.57 0.5 0.14
Dowd 1996 Week 5 0.48 0.55 0.07
Analysis 4.1. Comparison 4 Caffeine reduction versus control, Outcome 1 Mean quality of life scores.
Mean quality of life scores
Study Outcome Caffeine substitution Caffeine exposure Reported
P value
Wells 2011 ICIQ Overactive Bladder
(ICIQ-OAB) total score (N
= 11);
0-16 overall score with
greater values indicating in-
creased symptom severity
4.64 6.55 < 0.01
Wells 2011 ICIQ Overactive Bladder
Symptoms Quality of Life
(ICIQ-OABqol) score (N =
11); 25-160 overall score
with greater values indi-
cating increased impact on
quality of life
Wells 2011 1) How regularly bladder
symptoms interfered with
the ability to get a good
night’s rest
2.64 4.09 < 0.01
Wells 2011 2)Howoften bladder symp-
toms caused anxiety or
worry
1.73 2.64 < 0.05
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Mean quality of life scores (Continued)
Wells 2011 3) How much bladder
symptoms interfered with
everyday life overall
3.73 5.64 < 0.01
Wells 2011 4)Total scores for the ICIQ-
OABqol
53.91 68.36 0.065
Analysis 4.2. Comparison 4 Caffeine reduction versus control, Outcome 2 Mean number of UI episodes per
24 hours (SD).
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 4 Caffeine reduction versus control
Outcome: 2 Mean number of UI episodes per 24 hours (SD)
Study or subgroup Reduced caffeine Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bryant 2002 36 1.2 (1.9) 38 1.4 (1.7) -0.20 [ -1.02, 0.62 ]
-10 -5 0 5 10
Favours reduced caffeine Favours control
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Analysis 5.1. Comparison 5 Lifestyle weight loss versus metformin, Outcome 1 Prevalence of weekly UI
after intervention.
Review: Lifestyle interventions for the treatment of urinary incontinence in adults
Comparison: 5 Lifestyle weight loss versus metformin
Outcome: 1 Prevalence of weekly UI after intervention
Study or subgroup Lifestyle weight loss
Metformin
weight loss Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All UI types at 2.8 years
Brown 2006b 252/659 306/635 0.79 [ 0.70, 0.90 ]
2 Stress UI at 2.8 years
Brown 2006b 206/659 252/635 0.79 [ 0.68, 0.91 ]
3 Urgency UI at 2.8 years
Brown 2006b 156/659 182/635 0.83 [ 0.69, 0.99 ]
0.1 0.2 0.5 1 2 5 10
Favours lifestyle Favours metformin
A P P E N D I C E S
Appendix 1. Additional search of ClinicalTrials.gov
After themain searching for this review was completed, searching and assessment of 1151 records fromClinicalTrials.gov was completed
(date of last search: 28 November 2013; via the Central Register of Studies (CRS) software) using the following search terms:
Continent OR continence OR incontinent OR incontinence OR overactive OR overactivity (in the simple search command line)
After screening 1151 records we identified four that were potentially eligible for this review. As this search was completed after the
main search was completed (and its results had been fully incorporated into the review) these four trials were added to Studies awaiting
classification so that they can be fully assessed for the next version of the review.
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 12, 2015
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Date Event Description
7 July 2010 New citation required and minor changes new review authors
7 July 2010 Amended protocol amended
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the initial design and writing of the protocol. MI and KW led study selection, data abstraction and analysis,
and wrote the first draft. CM and MW provided critical revisions of the draft for important intellectual content. All authors provided
final approval of the version to publish.
D E C L A R A T I O N S O F I N T E R E S T
M Imamura: none known
K Williams: none known
MWells: none known
C McGrother: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant
or Cochrane Incentive funding to the Incontinence Group. The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Selection criteria for Types of participants has been amended after the review commenced. The protocol stated that only adults with
urinary incontinence (UI) would be considered for inclusion. Due to the limited number of studies that met this criterion, we also
included data from trials where some, but not all, participants had UI at baseline regardless of the proportion of people with UI or
availability of data subgrouped by incontinence status.
As the recommendation to assess the quality of evidence using the GRADE approach and also to include ’Summary of findings’ tables
became prominent during the course of the review, we attempted to undertake the assessment, even though this was not mentioned in
the protocol. The GRADE and ’Summary of findings’ outcomes were thus defined after the review commenced.
Searches of MEDLINE, EMBASE, CINAHL included in the specialised register, and searches of the reference lists of relevant articles,
had been planned originally but were not spelt out in the protocol. Descriptions of these searches have been added to the review for
the sake of clarity.
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ClinicalTrials.gov has been searched in response to a comment from an external referee.
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